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 Breast cancer is a complex disease affected by genetic, epigenetic and environmental 
factors. The genetic architecture of breast cancer comprises of high to low penetrance alleles. 
Although low penetrance alleles associate with a small change in an individual’s risk to breast 
cancer, the total number of variants present and the high population frequency attributes to a 
much greater population based impact compared to rare high penetrance alleles. Animal models 
have been used to study these low penetrance modifier alleles in breast cancer. Different rat 
strains vary in their susceptibility to 7,12- dimethybenzanthracene (DMBA) induced mammary 
carcinogenesis, with the Wistar- Furth (WF) rat being highly susceptible and the Copenhagen 
(Cop) strain being almost completely resistant to it. Linkage analysis performed to identify 
quantitative trait loci associated with DMBA induced mammary carcinoma susceptibility in the 
WF and Cop rats led to the identification of mammary carcinoma susceptibility loci 1-4 (Mcs1-4). 
This dissertation focuses on Mcs3 and Mcs1b. The Mcs3 locus was predicted across two peak 
marker on chromosome 1 D1Mit11 and D1Wox6. My work helped to physically confirm the 
Mcs3 locus and map it to a 25.8 Mb region on rat chromosome 1. The Mcs1b locus was mapped 
to a 1.8MB region on rat chromosome 2. denDekker et al 2012, showed that the Mcs1b locus and 
identified Mier3 as an Mcs1b candidate gene. My studies showed, the proportion of luminal 
mammary epithelial cells (MECs) was higher in Mcs1b resistant mammary epithelial cell 
enriched extracts (MEC extracts) compared to susceptible MEC extracts. This observation 
vi 
 
suggests that luminal MECs are potentially the target cells of DMBA induced carcinogenesis and 
future mechanistic studies could be conducted in luminal MECs. Expression assays on MEC 
extracts suggest that Mitogen-Activated Protein Kinase Kinase Kinase 1 (Map3k1), GC-Rich 
Promoter Binding Protein 1 (Gpbp1) and Mesoderm Induction Early Response 1, Family 
Member 3 alternative 5’ start site variant (Mier3-alt5P) are Mcs1b candidate genes. 
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Breast Cancer Statistics 
According to cancer statistics for 2016, breast cancer was the most frequently 
diagnosed cancer among women, preceded only by skin cancer, accounting for 231,840 
new cases or 29% of cancer diagnosed [1]. A woman’s risk of being diagnosed with 
breast cancer has increased from 1 in 11 in the 1970s to 1 in 8 in 2015. There are many 
factors contributing to the increase in breast cancer risk, which include longer life 
expectancy, and earlier diagnosis due to prophylactic measure [2]. Current and past 
research has focused on the detection and treatment of this disease, leading to a 34% drop 
in death rates since the 1990s [2]. However, despite these achievements, breast cancer 
remains the second leading cause of cancer-related death among women, accounting for 
15% of cancer-related death or 40,290 cases [3]. Thus, there is a need for further research 
to understand the mechanism, and to identify risk factors associated with the 
development of breast cancer. 
Breast Cancer Risk Factors 
Breast cancer is a complex disease controlled by environmental, genetic and 
epigenetic factors [2]. An individual’s risk to breast cancer is determined by many 
factors, including gender, age, family history, reproductive history, diet, alcohol use, 
lifestyle and environmental exposure [2, 4]. Gender accounts for the largest portion ofrisk 
to developing breast cancer, with women being more susceptible to breast cancer than 
men. Female breast cancer accounts for 99% of breast cancer cases diagnosed and breast 
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cancer-related deaths [3]. The following text will discuss some factors contributing to 
breast cancer risk in more detail. 
Age 
It is very uncommon for a woman in her 20s to be diagnosed with breast cancer, 
but risk increases with age and the probability of a woman developing breast cancer in 
her 90s being 1 in 5 [2, 5]. The prevalence of breast cancer is less than 10 cases per 
100,000 for women under the age of 25 years. This prevalence increases 100-fold by the 
age of 45, making it the leading cause of cancer-related death in women between the ages 
of 20 to 59 [3, 6]. Breast cancer etiology varies with age. Although young women are less 
likely to develop tumors, the tumors that they do develop tend to be more aggressive. 
Younger women develop more estrogen receptor (ER)-negative tumors compared to 
older women. This trend continues until about 60 years of age [7-9]. It was also found 
that, for women above the age of 60, luminal A is the most common breast cancer 
subtype, while in women below the age of 40, luminal A is the least common subtype [3, 
10]. Thus, age is not only an important factor in the development of breast cancer, but 
also in the prognosis and treatment of disease. 
Radiation 
Radiation exposure is also a strong risk factor for breast cancer, since breast tissue 
is very sensitive to radiation-induced carcinogenesis [11]. The current understanding of 
the relationship between ionizing radiation exposure and breast cancer risk was obtained 
from epidemiological studies of patients exposed to radiation for medical treatment and 
women exposed due to proximity to atomic bomb explosions [11, 12]. Age at exposure is 
inversely related to risk of developing breast cancer. This is thought to stem from the 
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degree of differentiation of breast tissue at age of exposure. In support, women below the 
age of 20 are more susceptible than women above the age of 45 [12, 13]. It was also 
found that the risk of developing breast cancer is proportional to the dose of radiation 
exposure [12, 14]. However, studies have shown that low-dose radiation, delivered over a 
period of time, e.g. under medical setting, can also have a long lasting cumulative effect 
that may cause breast cancer [13, 14]. Medical use of radiation is recommended only 
when the benefits outweigh the risks of exposure [15]. 
Alcohol Use 
A number of epidemiological studies have shown that alcohol consumption 
increases breast cancer risk [16-23]. Results of two meta-analyses suggest that an 
addition of 10 g of alcohol per day increases risk of breast cancer by 10% [24, 25]. It is 
worth noting that alcohol consumption is a risk factor associated with ER+ tumors [26, 
27]. The mechanism behind alcohol consumption and breast cancer development is not 
clearly understood. One hypothesis proposed is that alcohol contribute to breast cancer 
development by modulating sex hormone levels in women [28]. Another hypothesis 
proposed is that acetaldehyde, a known product of alcohol metabolism, is actually the 
main contributor to alcohol-induced carcinogenesis [29, 30]. Alcohol is an organic lipid 
solvent. Another theory proposed is that it may increase cell permeability to carcinogens 
by modulating cell membrane properties. Alcohol has also been shown to impair folate 
metabolism, thus influencing DNA methylation. Folate plays an important role in DNA 
methylation [29]. Alcohol intake may also enhance reactive oxygen species (ROS) 
production, modulate carcinogen metabolism, and inhibit DNA repair [31]. In part 
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because of the risk between alcohol consumption and breast cancer development, women 
are recommended to drink alcohol in moderation 1 drink/day [32]. 
Smoking 
Studies have shown smoking increases breast cancer risk by 10% [33, 34]. It was 
found that a woman has a higher risk if they started smoking many years prior to first 
pregnancy [34-37]. Results from the Canadian National Breast Screening Study (NBSS) 
indicate that breast cancer is associated with duration (40 years vs nonsmoker) of 
cigarette smoking, with a hazards ratio (HR) of 1.57 (95% CI = 1.29 – 1.92). The HR for 
the intensity (40 cigarettes per day vs nonsmoker) of cigarette smoking was 1.21 (95% CI 
= 1.04 – 1.40). Breast cancer was also found to be associated with cumulative exposure 
(40 pack years vs nonsmoker: HR = 1.09; 95% CI = 1.06 – 1.13) and latency (40 years 
since initiation vs nonsmoker: HR = 1.31; 95% CI = 1.10 – 1.53) of cigarette smoking 
[38]. Breast cancer is not historically considered a tobacco related cancer, but in vivo and 
in vitro studies have implicated cigarette smoke induces breast carcinogenesis [39]. 
Cigarette smoke has many well documented carcinogens, and mammary tissue is capable 
of taking up many of these carcinogens, including polycyclic aromatic hydrocarbons and 
N-nitrosamines [40]. Mammary epithelial cells (MECs) are capable of bio-activating 
these compounds into molecules that induce DNA-damage and -adduct formation [37, 
41]. N-acetyltransferase-2 (NAT2) is a polymorphic enzyme responsible for detoxifying 
aromatic and heterocyclic amines present in cigarette smoke. Women with a NAT2 slow 
acetylator phenotype have increased breast cancer risk [42]. Slow acetylators increase the 
exposure time to carcinogens, thus increasing susceptibility. The formation of DNA 
adducts were more common in slow acetylators [43]. Thus, genetics has a role in 
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cigarette smoke induced mammary carcinogenesis. This observation further proves that, 
breast cancer is a complex disease and many factors contribute to an individual’s risk of 
being diagnosed with it. 
Environmental Pollutants 
The two environmental pollutants most commonly associated with breast cancer 
are polycyclic aromatic hydrocarbons (PAHs) and polychlorinated biphenyls (PCBs). 
PAHs are genotoxic oxidants formed as a result of incomplete combustion and are found 
in tobacco smoke, diet, and indoor and outdoor air pollution, [44]. PAHs have been 
linked to breast cancer through several epidemiological studies [45-48] and have been 
shown to cause mammary cancer in animal studies [39]. PAH DNA adducts can cause 
DNA damage over the course of a few months to a year, depending on cell turnover rate 
[45, 49]. In addition, PAHs are lipophilic and can be stored in adipose tissue for a long 
time [47]. PCBs are found in lubricants, liquid sealants, flame retardants and electrical 
insulators [50]. Despite curtailing the production and distribution of PCBs by the Toxic 
Substances Control Act of 1976, PCBs remain persistent in certain environments due to 
improper disposal, leakage from industrial products, and chemical spills [51]. PCBs are 
classified as a group 1 carcinogen by the International Agency for Research on Cancer. 
PCBs are also lipophilic and accumulate in adipose tissue. The dioxin-like (coplanar) 
PCBs activate the aryl-hydrocarbon receptor (AhR) signal transduction pathway resulting 
in altered gene expression promotion of tumorigenesis [52-55]. On the other hand, non-
planar PCB congeners induce oxidative stress, DNA damage and apoptosis in 
mammalian cells [56-60]. 
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Lifestyle 
Many lifestyle choices can impact an individual’s risk to breast cancer. Not 
having children or having the first child after the age of 30, not breastfeeding, long term 
use of contraceptive pills, and the use of hormone replacement therapy increase risk to 
breast cancer [61]. High physical activity has been shown to reduce breast cancer risk in 
women, with an average of 20 to 25% reduction in breast cancer risk in women with a 
higher level of physical activity compared to women with lower level of physical activity 
[62-64]. In addition to physical activity, certain diet has been associated with improved 
breast cancer risk and disease progression [65]. A review by Davies et al. suggested that 
a diet high in fiber and low in fat might be protective against breast cancer progression 
and recurrence [66]. Another study showed that eating a minimum of five fruit and 
vegetable servings daily, while maintaining a physically active lifestyle, improved the 10 
year survival rate of breast cancer patients [67]. The American Cancer Society suggests 
that overweight and obese people reduce weight gain, adopt a physically active lifestyle, 
have a diet rich in vegetables and fiber-rich food, and reduce fat intake to reduce chances 
of developing breast cancer [68]. 
Estrogen 
In 1991, Women’s Health Initiative (WHI) research initiated a 15 year study on 
the beneficial effect of post-menopausal Hormone Replacement Therapy (HRT) on heart 
disease, cancer and bone fracture. This study had to be stopped prematurely in 2002 due 
to the increased incidence of breast cancer, stroke, and heart complications in the 
estrogen alone and the combination estrogen/progesterone treatment groups [69]. The US 
National Toxicology Program classified estrogens as carcinogens, the International 
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Agency for Research on Cancer (IARC) also classified both estrogens and 
estrogen/progesterone combined post-menopausal therapies as known carcinogens [70]. 
Epidemiological, animal, and in vitro studies indicate endogenous estrogens are involved 
in breast carcinogenesis [71]. Evidence towards estrogen’s role in breast cancer started 
with the observation that a double oophorectomy significantly reduces breast cancer risk 
[72]. Breast cancer risk factors, such as early onset of menarche (12 years), late onset of 
menopause (55 years), and having no children or having them late in life, are indicative 
of a lifetime of mammary tissue exposure to sex hormones [71]. 
Many mechanistic studies have been conducted to understand the role of 
estrogen-associated signal pathways in carcinogenesis. Estrogen increases c-Myc and 
cyclin D1 expression inducing cell proliferation; whereas, antiestrogen agents have a 
converse inhibitory effect [73]. Estrogen increases Bcl-2 and Bcl-XL expression in breast 
cancer cells and inhibits apoptosis [74]. In breast cancer cells, estrogen stimulates 
interleukin 8 and vascular endothelial growth factor secretion, both of which can 
potentially induce angiogenesis. As opposed to this, antiestrogen tamoxifen decreases 
tumor angiogenesis in ER+ breast cancer cells [75-77]. Research into the role of estrogen 
in breast tumor formation has led to the development of several antiestrogens as the 
primary breast cancer treatment given that two third of breast cancer is ER+. Surgical 
oophorectomy was the method chosen to treat women diagnosed with premenopausal 
breast cancer prior to the development of antiestrogens. The American Society Clinical 
Oncology no longer recommend oophorectomy for the treatment of breast cancer due to 
the success of antiestrogen drugs [78]. The first of these antiestrogen agents was 
tamoxifen, which was introduced in the 1970s. It is the preferred choice of treatment due 
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to its efficacy and low price. It is also used as adjuvant therapy to prevent breast cancer 
recurrence in both pre and postmenopausal women [79]. The introduction of tamoxifen 
was followed by the rapid development of selective estrogen modulators (SERMs) and 
aromatase inhibitors (AI). SERMS, a group of compounds which are structurally similar 
to estrogens, can bind to and modulate estrogen receptor (ER) function in different tissues 
[80]. In addition to tamoxifen, the FDA has approved two other SERMs, toremifene and 
raloxifene. Toremifene has antiestrogen activity in the mammary gland. It is used to treat 
postmenopausal women with metastatic breast cancer. Raloxifene is a second generation 
drug with a secondary use in osteoporosis prevention [81]. Fulvestrant is a third-line 
treatment for postmenopausal women that have ER+ tumors. It modulates ER by 
promoting ER turnover in cells [82, 83]. In addition to SERMs, another class of agents 
for the treatment for breast cancer was developed based on the observation that breast 
cancer tissue has higher levels of estrogen compared to non-cancerous cells. Aromatase 
catalyzes the final rate limiting step of estrogen synthesis. AIs (e.g. anastrazole, letrozole 
and exmestane) are used to treat breast cancer in postmenopausal women [84]. 
Epigenetics 
Many studies have implicated epigenetic changes in breast cancer pathogenesis. 
DNA methylation and post translational histone modification are the main epigenetic 
modifications associated with breast cancer. Hypermethylation of promoter CpG islands 
is one method of gene inactivation which could occur in the initial stages of breast cancer 
development. In one study, 802 breast tumors were examined by the Cancer Genome 
Atlas Network. This work resulted in identifying many genes that are differentially 
methylated [85]. Many of these aberrantly methylated genes play critical roles in 
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apoptosis, cell cycle regulation, tumor suppression, angiogenesis, epithelial-mesenchymal 
transition (EMT) and metastasis [86, 87]. Studies have also shown how methylation 
changes can be an early sign of developing breast cancer and correlate with the 
development of breast cancer [88]. Methylation of genes like GHSR can be used to 
differentiate breast cancer from normal breast tissue [89]. Studies also suggest that higher 
level of methylation is indicative of more aggressive metastatic breast cancer [90]. Hyper 
methylation of pro-apoptotic gene (HOXA5, TMS1), cell cycle inhibitors (p16, 
RASSF1A), and DNA repair genes (BRCA1) have been identified in metastatic breast 
cancer cells [91]. Distinct patterns of posttranslational histone modification have been 
observed in breast cancer. DNA methyltransferases (DNMTs) and histone 
desacetyltransferase (HDAC) are highly expressed in the promoter of the ER gene, 
inactivating ER in ER negative breast cancer [92, 93]. Histone modification leads to the 
down regulation of E-cadherin which is necessary for the initiation of EMT [94]. 
Genetics 
The genetic component of breast cancer development was first noted with the 
observation that there is a higher prevalence of breast cancer in monozygotic twins of 
patients compared to dizygotic twins or siblings of patient. The incidence is also high in 
1
st
 degree relatives of breast cancer patients. This risk is greater for individuals with more 
affected relatives and is also greater if these relatives were diagnosed at a younger age 
[95-98]. Approximately 5 to 10% of breast cancer cases are autosomal dominant, 
following a Mendelian pattern of inheritance. Another 15 to 20% of breast cancer cases 
are familial (women with first or second degree relatives that have the disease). Among 
hereditary breast cancer cases, 30% are attributed to germline mutations in high 
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penetrance alleles of BRCA1 and BRCA2 [3, 99]. Studies over the past two decades have 
shown that the genetic component of breast cancer susceptibility is complex and 
comprises of genetic variation at many different loci. These susceptibility alleles differ in 
their population based frequency and the relative risk that they confer. The genetic 
component of breast cancer susceptibility comprises of high penetrance alleles, moderate 
penetrance alleles and low penetrance alleles. As shown in figure 1, high penetrance 
alleles confer a greater than 50% of the lifetime risk of breast cancer, moderate 
penetrance alleles confer a lifetime risk of 20% or more; whereas, low penetrance alleles 
confers a lifetime risk of 10 to 20% [100]. 
High Penetrance Alleles 
High penetrance alleles affect individuals, usually at a younger age and are 
present in some families with a breast cancer history. Such families were subjected to 
linkage analysis and positional cloning to identify high penetrance alleles in BRCA1 and 
BRCA2, two tumor suppressors which are involved in DNA repair [101, 102]. These 
genes are relatively rare in a given population, they have a cumulative frequency of 1 in 
800 for BRCA1 mutations and 1 in 500 for BRCA2 mutations and they confer an 85% risk 
by the age of 70 [103, 104]. Mutations in BRCA1 and BRCA2 are responsible for 
approximately 84% of families with more than 3 members diagnosed with breast cancer 
at younger than 60 years of age [103]. Other high penetrance alleles have been identified 
by studying syndromes with inherited cancers as a symptom. TP53 mutations were 




Figure 1. Genetic Architecture of Breast Cancer Susceptibility. Adapted from 
Ghouussani et al (2013). Figure shows the relative risk associated with different risk 
alleles as a plot against its respective allele frequency. Genes associated with breast 
cancer risk are further classified into groups based on level of risk.
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BRCA1 and BRCA2 
In 1990, BRCA1 was the first major gene associated with hereditary breast cancer. 
It is present on chromosome 17 and was identified by linkage analysis of individuals in 
families with a history of breast cancer [107]. BRCA1 is involved in homologous 
recombination to repair double stranded breaks in DNA [108]. BRCA1 is also involved in 
cell cycle control, as an upregulation of BRCA1 results in upregulation of p21 and G1-S 
cell cycle arrest [109]. In 1994, BRCA2 was associated with increased risk to breast 
cancer in a genetic maping project focused on chromosome 13 [110]. Like BRCA1, 
BRCA2 is also involved in DNA damage repair by homologous recombination [111]. 
Individuals with BRCA mutations are said to have Hereditary Breast/Ovarian Cancer 
Syndrome (HBOC). BRCA1 related tumors tend to be ER, PR and Her2/neu negative 
while BRCA2 related tumors are ER positive [112, 113]. BRCA mutations are inherited 
in an autosomal dominant fashion, but act recessively to bring about a phenotype of 
cancer. This is because loss of both copies is required, as these tumor suppressor genes 
are involved in double stranded DNA break repair [114]. BRCA1 mutation carriers have a 
10 to 40% lifetime risk whereas BRCA2 carriers have 10 to 20% lifetime risk of ovarian 
cancer [115]. Inherited biallelic BRCA2 mutations result in a Fanconi anemia type D1 
like phenotype while inherited biallelic mutations in BRCA1 are not documented, as this 
condition is likely embryonic lethal [114]. Women with BRCA mutations should be 
counseled regarding breast awareness and breast self-exam by 18 years of age. Annual 
MRI checkup is usually recommended from 25 years of age. Risk-reducing salpingo-
oopherectomy (RRSO) is recommended after the age of 35 based on family history and 
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reproductive history. Prophylactic mastectomy is also frequently considered due to high 
lifetime risk and risk of secondary breast cancer [116-118]. 
Moderate Penetrance Alleles 
Moderate penetrance alleles have been identified by resequencing genes that 
interact with BRCA1 and BRCA2, or those which are a part of DNA repair pathways. 
Variants of ATM, CHEK2, PALB2 and BRIP1 show a 2 to 4 fold increase in breast cancer 
risk [119-123]. Linkage studies in families with rare syndromes that affect the breast, led 
to the identification of PTEN and CDH1. PTEN and CDH1. All confer a relative risk of 
two to eight [124, 125]. Altogether these genes account for less than 25% of risk 
associated with familial breast cancer [126]. 
CHEK2 
CHEK2*1100delC is the most common CHEK2 polymorphism, present in 1 to 
2% of European population. This gene can have a prevalence as high as 5% in breast 
cancer patients with a family history of breast cancer but BRCA1 or BRCA2 mutation 
negative [121] . CHEK2 is involved in cell cycle regulation at the G2 phase. It is a kinase 
that is phosphorylated in response to DNA damage. Activated CHEK2 interacts with 
BRCA2 while stabilizing BRCA1 [127]. Individuals who are co-carriers of CHEK2 
mutations and BRCA1 or BRCA2 mutations do not have an additional increase in risk as 
they induce overlapping effects on DNA repair [121]. As with BRCA1 there is no known 
biallelic phenotype for CHEK2, indicating this condition may be embryonic lethal [114]. 
BRIP1 
BRIP1 (BACH1) mutations account for less than 1% of breast cancer cases. 
Individuals with a history of breast cancer with BRIP mutations have a 2.0 relative risk of 
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developing breast cancer. These individuals have a higher risk for the early onset of 
breast cancer. BRIP1 interacts with BRCA1 C-Terminius (BRCT) domain of BRCA1. 
Most of the mutations identified are protein truncating. Individuals that are biallelic for 
BRIP1 mutations are associated with Fanconi anemia type J; these patients do not have a 
significant increase in cancer during their childhood [119]. 
Low Penetrance Alleles  
Low-penetrance breast cancer risk-associated alleles are fairly common in the 
population, many having a minor allele frequency of greater than 5% and each attributing 
to a small change in an individual’s risk to breast cancer (relative risk of less than 1.5). 
Low penetrance alleles in the past have been identified in the past by case-control 
association studies, where candidate genes based on their known function are studied 
[128, 129]. This method is biased and may miss out on genes that are not yet functionally 
characterized. Since the advent of better genotyping technology, genome wide 
association studies (GWAS) have become possible. GWAS have led to the identification 
of over 70 breast cancer susceptibility loci. These loci however only explain 14% of 
familial breast cancer [100]. There is also some evidence that relative risk of low 
penetrance alleles are modified by environmental risk factors like life style and 
reproductive history [130]. Thus, there are many low penetrance alleles that remain to be 
identified. 
Rs889312 
5q11.2 SNP (rs889312) was one of the SNPS identified in a GWAS to associate 
with breast cancer susceptibility in a population with European ancestry [131]. The minor 
allele for rs889312 was found to associate with a per allele odds ratio of 1.12 (95% CI = 
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1.10 – 1.15, ptrend = 1.8x10
-26
) in the most recent Breast Cancer Association Consortium 
(BCAC) [132]. The association was strongest for ER+ disease (OR = 1.14, 95% CI = 
1.11 – 1.17, p = 1.1x10-26), but was also seen for ER- (OR = 1.06, 95% CI = 1.03 – 1.10, 
p = 0.0024) and triple negative disease (OR = 1.11, 95% CI = 1.02 – 1.20, p = 0.016) 
[133]. Carriers with BRCA2 mutations associated with a greater risk of developing breast 
cancer if they carried the minor allele of SNP rs889312 [134]. Rs889312 is located in a 
disequilibrium block (LD block) which contains three genes, MAP3K1, STED9 and 
MIER3. MAP3K1 was considered as the candidate gene due to its driver mutations 
observed in Luminal A and Luminal B breast tumors and other breast tumor sub types 
[135, 136]. However, the study was not conclusive; and thus, any of the three genes or 
combination thereof within the LD block and any of the SNPs that are in linkage 
disequilibrium with rs889312 could be the gene(s) or SNP(s) causing breast cancer 
susceptibility. Rats do not express a transcript of this gene [137]. MIER3, however, is 
more highly expressed in breast tumors compared to normal breast tissue, making it a 
candidate gene for a potential role in mammary carcinogenesis [137] This genomic 
region needs to be studied further to understand its role in female breast and rat 
mammary carcinogenesis. 
Animal Models of Breast Cancer 
There is no perfect experimental model to study breast cancer, but knowledge 
obtained from various models helps us to better understand this disease. Cell cultures are 
the simplest and most practical model to use. However, it is an oversimplified model and 
does not represent a complex in vivo tumor environment. Animal models come close in 
representing the multi-organ complexity of breast cancer. It is important to remember that 
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breast cancer represents an array of diseases and different experimental models are 
needed to represent and study different aspects of this array of diseases. 
Breast Cancer Cell Lines 
Breast cancer cell (BCC) lines used in vitro and in vivo studies have contributed 
significantly to the current knowledge regarding breast cancer. BCC lines, like any other 
model, have advantages and disadvantages. One of the main advantages is that it provides 
a homogenous, self-replicating model which can easily and quickly be cultured in simple 
growth media. BCC lines have been studied for more than 5 decades with the first cell 
line BT-20 described in 1958 [138]. Most BCC lines were established in the 1970s. A 
select few of them, namely, MCF-7, T-47D, MDA-MB-231 account for a majority of the 
research published [139]. Despite their role in understanding breast cancer, there are a lot 
of concerns regarding BCC lines being a representative model. It is usually the study of a 
single cell line which does not replicate or represent complex environments presented by 
the milieu of cells and interstitial fluid present in breast tissue or tumor environments. 
BCC lines are genetically unstable and long, stressful culture conditions can lead to its 
genotypic and phenotypic alteration. These changes lead to discrepancies in data 
interpretation and difficulties in replicating results [140]. One way of overcoming these 
short comings is by using an animal model to study breast cancer. 
Canine Models 
Mammary cancer is the second most common cancer in dogs. It is the most 
frequently diagnosed tumor in female dogs accounting for 52% of tumors diagnosed 
[140]. Canine mammary cancer is similar to human breast cancer with respect to tumor 
establishment and metastatic progression [141]. Canine mammary tumor like human 
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breast tumors are hormone dependent [142]. There is a significant overlap between 
canine and human genes that are deregulated in mammary cancer. Studies have shown 
that the deregulation of BRCA1 and BRCA2 are associated with mammary tumor 
development in dogs [143]. In another study, gene expression profiles from both human 
breast and dog mammary tumors were compared to normal breast and mammary tissue 
from the respective species. This study showed that in both species, similar pathways, 
related to increase in proliferation activity, were upregulated; whereas, similar pathways 
related to cell development, cell communication and cell matrix adhesion were down 
regulated. Cancer-related pathways like phosphatidylinositol 3-kinase (PI3K)/AKT 
pathway, KRAS, phosphatase and tensin homolog (PTEN), Wnt-b-catenin, and mitogen-
activated protein kinase (MAPK) cascade were altered in both human and canine tumors 
[143]. The close similarities between canine and human mammary cancer makes dogs an 
appealing model to study human breast cancer. However, the disadvantages to using a 
canine model include its large body size, higher cost of housing, longer life span and 
fewer genetic tools available for manipulation as compared to its smaller, more easily 
housed rodent counterparts, which have a shorter life span. 
Mouse Models 
The mouse is an extremely popular model to study human breast cancer. The 
biology of mouse mammary gland has been studied and well characterized over many 
years with respect to normal development, changes occurring during lactation and 
developing spontaneous tumors. The popularity of the mouse as a model arises from its 
short lifespan, small size, feasible housing cost, ease of breeding in captivity and a well-
defined genome [144]. 
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Mice have been an extremely useful as xenograft and genetically engineered 
(GEM) models to study breast cancer. Several mammary specific gene promoters have 
been characterized enabling mammary specific engineering of genes. Several approaches 
have been used to genetically engineer mice [145]. One of the approaches is to create a 
transgenic (TG) mouse. Here, the gene of interest, like C-myc or Ras is randomly inserted 
into the germline by directly injecting DNA into one of the two pronuclei of a fertilized 
egg [146]. These mice have specific oncogene expression, usually controlled by 
mammary gland specific promoters. TG mice provide the option of testing human genes 
implicated in breast cancer in an in vivo setting [147]. Another mouse model which has 
been very beneficial to the study of breast cancer is the human to mouse xenograft model. 
Here, human cancer cells are grafted into the mouse resulting in a tumor with human 
cancer cells within the murine stromal cells [148]. Another approach, preferred to study 
tumor suppressor genes, like BRCA1 and BRCA2, involves the generation of knock out 
mice. A nonfunctional version of the gene of interest is introduced into mouse embryonic 
stem (ES) cells. Cells with the targeted “knockout” gene, integrated by homologous 
recombination at the homologous site are selected. The resulting ES cells are used to 
generate the desired knock out mouse. A disadvantage of this model is that it is not an 
accurate representation of gene expression as most tumor-associated mutations are 
somatic and are only present in tumor cells and not globally expressed. Another 
disadvantage of this approach is that global inactivation of some genes often lead to 
embryonic lethality. This shortcoming led to the development of the next approach to be 
described where genes can be modified in the germline, but inactivated in a tissue 
specific and time specific manner. The most established method for tissue specific 
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knockout uses the Cre/Lox recombinase system [149]. LoxP are 34bp long genetic 
elements which are recognized by Cre recombinase enzyme. Knock in mice with two Lox 
sites on either end of the gene of interest are generated. These mice are still functionally 
normal despite the Lox elements. The knock in mice are then crossed with transgenic 
mice expressing Cre recombinase, which is controlled by tissue specific promoter, Cre 
mediated recombination occurs, resulting in tissue specific knock out of the gene of 
interest. 
Despite its many advantages, a mouse model of breast cancer has its limitations. 
They do not best represent human tumors with respect to, growth over long periods of 
time, the role the immune system plays, and the heterogeneity observed in tumor cell, 
microenvironment and stroma [150, 151]. Another limitation observed is that mouse 
models are not predictive of tumor development in human tumors with the same 
histology [152]. Biologic differences, such as functionally active telomerase in murine 
cells unlike human cells, could affect oncogenesis [153, 154]. A majority of human breast 
tumors are estrogen responsive, while mouse mammary tumors are generally estrogen 
independent. Also, in most murine models, metastases occur hematogenously, and the 
primary site of metastasis is the lung. In humans, breast cancer is characterized by 
lymphatic and nodal metastases in addition to hematogenous metastases and sites of 
metastasis include lung, liver, bone, and brain [155]. 
Rat Models 
Rats are another popular rodent model used to study breast cancer. Rat mammary 
cancer is very similar to human breast cancer with respect to histopathology, cell type of 
origin, and hormone responsiveness. The histologic features of malignant tumors in rats 
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are similar to intraductal and infiltrating ductal carcinomas in humans. Also, 
fibroadenomas (FA) and adenomas are similar in rats and humans [156, 157]. In rat 
mammary cancer, it was found that initiation of carcinogenesis occurs in the epithelium 
of terminal end buds (TEBs) while they are developing into alveolar buds (ABs) and 
terminal ducts (TDs). The TEBs in rat mammary glands are considered to be equivalent 
to the terminal ductal lobular unit (TDLU) in the human breast [156, 158]. Preexisting 
FA undergo rapid growth during pregnancy suggesting estrogen responsiveness. This 
pattern of rapid growth of ducts, cells lining ducts amount of periductal fibrous tissue 
found in FA is observed when both rat and human mammary glands are treated with high 
doses of estrogen[159]. 
Rat Models and Chemical Carcinogens 
In addition to hormones, chemical carcinogens, like 7,12-
dimethylbenz[a]anthracene (DMBA) and N-Nitroso-N-methylurea (NMU), have been 
used experimentally to induce mammary cancer in rats. DMBA is usually administered as 
a single dose of 2.5 – 20 mg by oral gavage. DMBA needs to be bioactivated to induce 
carcinogenesis. NMU is also administered as a single dose of 25 – 50 mg/kg body weight 
by intravenous, intraperitoneal, or subcutaneous injections. Both carcinogens usually 
induce 100% tumorigenesis by 8-21 weeks [160]. Tumor number, latency and incidence 
are a function of carcinogen dose administered. [161]. DMBA or NMU induced 
carcinogenesis is age dependent and optimal at the age of sexual maturity which is 45 to 
60 days of age in rats. Sexual maturity is marked by active organogenesis and glandular 
epithelial proliferation [162-165]. 
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DMBA Induced Rat Mammary Carcinogenesis 
In 1961, DMBA was reported to be a very specific and efficacious carcinogen to 
induce mammary carcinogenesis in female rats [166]. DMBA induced mammary 
carcinogenesis is dependent on the strain of the rat, age at DMBA administration, 
topographic location of the mammary gland and reproductive history [166, 167]. DMBA 
is a preferred carcinogen because it reliably induces mammary tumors and provides organ 
specificity; further, mammary tumors generated are of ductal origin and hormone 
responsive [168]. However, one limitation in the use of DMBA is that mammary 
carcinomas induced by DMBA do not metastasize [169]. DMBA rat model has provided 
several insights on the mode of carcinogenesis. DMBA induced carcinogenesis acts on 
the intermediate cells of the terminal end buds (TEB) resulting in intraductal 
proliferations and carcinoma in situ [156]. This provides an excellent model to study and 
identify mechanisms of breast cancer progression. 
DMBA and Mammary Cancer Associated Quantitative Trait Loci (QTL) in the Rat 
Genome 
Different strains of rats vary in their susceptibility to DMBA induced mammary 
cancer. This difference in susceptibility is not due to a difference in the ability of these 
strains to metabolize DMBA [170]. Studies have shown a genetic basis for the observed 
differential susceptibility to DMBA induced mammary carcinogenesis. The Wistar-Furth 
(WF) rat is highly susceptible while the Copenhagen (Cop) rat and Wistar-Kyoto (WKy) 
rats are highly resistant to DMBA induced mammary carcinogenesis [171]. Genetic 
linkage analysis performed on (WF × Cop) F1 × WF backcross (BC1) rats using tumor 
number post-DMBA administration as the phenotype. Microsatellite markers were used 
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to determine the genotype of rats that were phenotyped. This led to the identification of 
mammary carcinoma susceptibility locus 1 (Mcs1) on rat chromosome 2 as a locus that 
reduces mammary carcinoma susceptibility [172]. In an extension to this study, BC1 rats 
were further studied along with a linkage analysis performed on a panel of BC1 × BC1 
backcross (BC2) rats and F2 (F1 × F1) rats to identify Mcs2, Mcs3, and Mcs4 on rat 
chromosome 7, 1 and 8 respectively. Mcs1, Mcs2, and Mcs3 loci reduce susceptibility of 
the susceptible strain, while Mcs4 increases DMBA induced mammary carcinoma 
susceptibility [173]. A similar linkage analysis, performed using the susceptible WF rat 
and resistant WKy rat, led to the identification of Mcs5, Mcs6, Mcs7, and Mcs8 on rat 
chromosome 5, 7, 10 and 14, respectively. Mcs5, Mcs6 and Mcs8 are associated with 
decreased susceptibility, while Mcs7 is associated with increased susceptibility to DMBA 
induced mammary carcinogenesis compared to the susceptible strain phenotype [174]. 
All loci except Mcs3 and Mcs7 have been studied beyond the initial mapping studies. 
To study the Mcs loci congenic rats were generated using the scheme displayed in 
figure 2. These congenic rats contain only the Cop or WKy allele of interest on a 
completely WF genetic background. To generate congenic rats, homozygous rats of the 
parent strains are bred to generate heterozygous F1 rats (Cop × WF or Wky × WF). The 
F1 rats are backcrossed with the susceptible WF parent to generate N2 rats. These rats are 
then successively backcrossed with the susceptible WF parent by selecting carrier rats 
with Cop or WKy allele of interest at each generation. Microsatellite markers and/or 
single nucleotide variants are used to genotype these rats to select carrier rats with the 
genotype of interest. The carriers are backcrossed for up to ten generations at which point 
the congenic rats usually only carry the Cop or WKy allele of interest on a completely 
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susceptible WF genetic background. These congenic rats are then used to study the Mcs 
locus of interest. 
So far, Mcs5 is one of the most studied Mcs locus. Mcs5 was initially predicted as 




















Figure 2. Generation of Congenic Lines. Susceptible rat strain is crossed with a 
resistant rat strain. The F1 generation is backcrossed with the susceptible parent strain, 
and subsequent offspring are backcrossed to the susceptible strain for ten generation by 
selecting for rats with the desired genotype. By the tenth backcross, the congenic rat with 
desired allele from the resistant rat strain, present on a completely susceptible genetic 
background is generated. The red and green bars represent the DNA from the different 
parent rat strains. The green bars indicate DNA from the susceptible rat strain and the red 
bars indicate DNA from the resistant rat strain. 
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performed on WKy and WF rats and was later physically confirmed as independently 
acting locus on rat chromosome 5 [174, 175]. Fine mapping this locus led to the 
identification of Mcs5a, Mcs5b, and Mcs5c loci. Mcs5a and Mcs5c reduce mammary 
carcinoma susceptibility while Mcs5b increases mammary carcinoma susceptibility in 
WF.WKy congenic rats compared to WF rats [176]. Studying each allele of these loci 
showed that neither the WF nor the WKy Mcs5a allele is dominant. Mcs5a and Mcs5b 
have an epistatic interaction where the Mcs5a allele masks the increased susceptibility of 
the Mcs5b allele. Mcs5a and Mcs5c interact synergistically to reduce mammary 
carcinoma susceptibility below the additive effect of the Mcs5 alleles at each locus 
independently [176].  
Fine mapping the Mcs5a locus showed that it contained 2 genetic elements, 
Mcs5a1 and Mcs5a2. Thus, Mcs5a is a compound locus and is functional only when the 
Wky allele Mcs5a1 and Mcs5a2 are in cis confirmation on the same chromosome. 
Mcs5a1 is located within Fbxo10 and the Mcs5a2 includes the 5’ region of Frmpd1. 
Fbxo10 was differentially expressed in thymus and Frmpd1 was differentially expressed 
in the thymus of congenic rats compared to the WF control rats. Also, a study of the 
orthologous region in humans identified MCS5A1 and MCS5A2 as alleles with high 
population based risk and low population frequency [177]. Mcs5a Wky allele is 
associated with γδTCR+ T-cells proliferation and cytokine production in mammary 
epithelium exposed to carcinogens [178]. Mcs5a modulates mammary carcinoma 
susceptibility by a chromatin looping mechanism to down regulate Fbxo10 expression in 
T cells in both humans and rats [179]. In a recent study it was found that c-Fos binds 
AP1- specific DNA elements in Mcs5a1, thereby regulating FBXO10/Fbxo10 expression 
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by a PKC-dependent pathway [180]. Mcs5a is a prime example of how the rat has been 
used as a model to study the mechanism of human breast cancer susceptibility. 
Mcs3  
The work presented in this dissertation will focus on two different mammary 
carcinoma susceptibility loci, Mcs3 and Mcs1b. In contrast to the Mcs5 locus, which is 
well characterized, little is known about genetic variants associated with Mcs3 and its 
underlying mechanism. Mcs3 is a locus predicted on chromosome 1 across two peak 
markers D1Mit11 and D1Wox6 as shown in figure 3. Mcs3 was predicted in a genetic 
linkage analysis using the WF and Cop rats. The Mcs3 Cop allele was predicted to 
associate with reduced tumor number as compared to its WF allele [173]. Since, the Mcs3 
locus is predicted at two peak markers, which are 29Mb apart, its exact physical location 
and architecture may be complex. It may be a complex locus due to additive [181], 
dominant, epistatic, and synthetic [177] effects of low penetrance genes. The mechanism 
of action of a predicted locus and its complexity can be better identified by mapping the 
locus to as small a chromosomal region as possible. Also, for human studies it is 
convenient to map to a region of shared synteny. Thus, both physical confirmation and 
positional mapping of this region are necessary. 
Mcs1b 
The second part of this dissertation focuses on the Mcs1b locus. Mcs1 rats 
developed an average of 1.2 tumors per rat post DMBA administration which was 
significantly lower than the WF rats which developed an average of 8.5 tumors per rat. 
Mcs1 was confirmed as a locus that reduces mammary carcinoma susceptibility [172]. To 
analyze the complexity of the Mcs1 locus, different recombinant congenic lines 
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Figure 3. Representation of Predicted Mcs3 Locus. Figure represents the Mcs3 locus 
which is predicted on rat Chromosome 1 across two peak markers D1Mit11 and D1Wox6. 




with varying lengths of the Cop allele at the Mcs1 locus were generated and phenotyped. 
This led to the identification of Mcs1a, Mcs1b, and Mcs1c loci, all of which reduce 
susceptibility to mammary carcinogenesis. [181]. Mammary gland grafting assays later 
showed that the Mcs1b locus acts in a mammary gland autonomous manner. The Mcs1b 
locus is of particular interest since it is orthologous to a GWAS identified locus 
associated with increased breast cancer incidence [131]. Haag et al. initially defined the 
Mcs1b locus between markers D2Uwm17 proximally and D2Rat16 distally 
(~13cM/11Mb) [181]. Recent work in our lab has delineated the Mcs1b locus to a 1.8 Mb 
region of rat chromosome 2 which is represented by congenic line N3 in figure 4 [137]. 
Mcs1b heterozygous congenic rats tested by Haag et al. developed an average of 7.6 
tumors/rat [181]; whereas Mcs1b heterozygous congenic rats tested by denDekker et al. 
developed around 5.5 tumors/rat [137]. This discrepancy in tumors developed by rats that 
are heterozygous Cop at the 1b-11 locus observed in two different studies could be 
indicative of a complex genetic interaction within the Mcs1b locus. To continue fine-
mapping Mcs1b, it is essential to generate recombinant congenic rats with smaller regions 
of the Mcs1b locus. Backcrossing line T (figure 4) generated the congenic line 1b-11 
which spans the distal end of the Mcs1b locus. A preliminary number of 1b-11 rats have 
been phenotyped, but more 1b-11 (figure 4) rats need to be phenotyped to determine the 
effect of Cop 1b-11 allele on susceptibility to DMBA-induced mammary carcinogenesis. 
Results from the same study by denDekker et al. that reported Mcs1b acts in a 
mammary gland cell autonomous manner, suggest that Mcs1b is a non-protein coding 
genetic element [137]. Mcs1b associated phenotypes include altered expression levels of 
Map3k1, Il6st, Gpbp1 and mesoderm induction early response1, family member3 (Mier3) 
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Figure 4. WF.Cop Congenic Map that Defines the Mcs1b Locus. Figure represents 
varying segments on rat chromosome 2 where Mcs1b was predicted to be located and 
congenic lines that were used to fine-map this locus. On the X axis, blue lines represent 
informative microsatellite markers, red lines represent informative SNPs, and green lines 
represent informative indels. Brown bars represent Cop alleles in congenic lines with a 
resistant phenotype, yellow bars represent congenic lines with a susceptible phenotype, 
white bars represent congenic lines with an unknown phenotype and grey bars represent a 
potential area of recombination where the genotype isn’t determined. The horizontal blue 
bar represents the orthologous region to human 5q11.2 breast cancer risk (BRCR) 
associated haplotype block. 
  
 31 
in mammary glands. Of all the genes contained within the Mcs1b region only Mier3 was 
differentially expressed between the mammary glands of Mcs1b resistant and susceptible 
WF rats with or without DMBA administration. Mier3 expression was 4.5 fold lower in 
mammary glands of the resistant congenic rats compared to susceptible WF rats [137]. 
These differential expression patterns were not observed in corresponding spleen, 
thymus, ovary or brain tissues; therefore, Mier3 transcript levels vary specifically 
between susceptibility genotypes in mammary gland tissue. It was also found that Mier3 
transcript level was 1.8 times higher in mammary carcinomas as compared to 
surrounding disease-free mammary tissue; human MIER3 levels were respectively 1.33 
and 1.20 times higher in invasive ductal and invasive lobular carcinoma samples 
compared to normal breast tissue [137, 182]. Thus, MIER3 is a potential candidate breast 
cancer susceptibility gene. MIER3 is an uncharacterized gene with a protein product 
localized to the nucleus [137]. Immunohistochemistry staining for Mier3 in mammary 
gland tissue of congenic rats showed that it is not uniformly expressed in all cell types but 
is specific to a sub-population of epithelial cells lining the duct (figure 5). It was also 
identified that an alternative 5’ transcriptional start site variant of Mier3 is differentially 
expressed between Mcs1b congenic and WF rat mammary glands compared to other 
Mier3 variants [137]. Differentially expressed 5’ start variants are typically indicative of 
cell or tissue type specific expression. Hence, it is possible that Mier3 is either 
responsible for reduced susceptibility to mammary carcinomas conferred by Mcs1b, or it 




Figure 5. Expression of Rat Mier3 in Cells Lining Mammary Ducts. Figure displays 
IHC staining for Mier3 as compared to IgG in transverse sections of rat mammary gland. 
Red arrows point to a rat mammary duct. The first panel shows an H&E stained section 
to observer the general layout of the tissue, the second panel shows the same section IHC 
stained for IgG, and the third panel shows this IHC stained section for Mier3.
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Overall Goals 
This goal of this dissertation work is two fold. The first goal will be to confirm 
the existence of predicted mammary carcinoma susceptibility QTL on RN01 named 
Mcs3. If confirmed, this can potentially lead to the discovery of new mammary 
carcinoma susceptibility modifiers and related mechanisms. The second goal of this 
dissertation work will be to further characterize the Mcs1b locus. The Mcs1b locus can be 
delineated to a shorter region on chromosome 2 or a complex interaction in this region 
may be identified; either of these results will help identify susceptibility modifier 
mechanism. Mier3 is either an ortholog of a candidate breast cancer susceptibility gene or 
a potential marker of a cell or tissue type that contributes to or explains altered mammary 
carcinoma susceptibility. Experiments proposed will help identify which of these roles 
Mier3 plays in mammary carcinoma susceptibility. 
Hypotheses 
Hypotheses 1 
Mcs3 QTL is an independently acting mammary carcinoma susceptibility locus on 
RN01. Mcs3 may have at least two independently acting sub-loci corresponding to two 
peak linkage analysis markers within this region.  
Hypotheses 2 
Mcs1b is a complex locus which alters DMBA-induced mammary carcinoma 
susceptibility. Congenic line 1b-11 contains a genetic element/s responsible for the 
Mcs1b associated phenotypes.  
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Hypotheses 3 
Differential mammary gland expression levels of Mier3 between Mcs1b line N3 
and susceptible WF females are due to a difference in MEC numbers between mammary 
glands of WF and Mcs1b congenic rats. 
Specific Aims 
These hypotheses will be tested by the following aims: 
Specific Aim 1 
Physically confirm predicted mammary carcinoma susceptibility QTL on RN01 
named Mcs3 using WF.Cop congenic rats. I will simultaneously determine if, Mcs3 is 
defined by two independently acting sub-loci. 
Specific Aim 2 
To determine if the WF.Cop line 1b-11 allele alters Mcs1b associated phenotypes. 
Specific Aim 3 
To determine if Mier3 is differentially expressed due to mammary epithelial cell 
population differences between congenic N3 and WF rats. 
To determine if Mier3 levels are lower in mammary gland tissue of Mcs1b rats 
due to genotype associated differences in mammary gland epithelial cell numbers. 
To determine if Mier3 is differentially expressed in mammary gland tissue of 
Mcs1b-resistant and Mcs1b -susceptible rats due to a difference in Mier3 expression 
levels in a population enriched for mammary gland epithelial cell.
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CHAPTER II 
MAMMARY CARCINOMA SUSCEPTIBILITY LOCUS, MCS3: 
PHYSICAL CONFIRMATION AND COMPARATIVE GENOMICS 
Introduction 
According to cancer statistics for 2016, breast cancer will be the most commonly 
diagnosed cancer among women, accounting for 29% of cancers diagnosed and 14% of 
cancer related deaths in women. Women have a population-based estimated 1 in 8 chance 
of being diagnosed with breast cancer in their lifetime [1]. It is a complex disease 
controlled by genetic, epigenetic and environmental factors. The genetic component of 
breast cancer susceptibility is comprised of high to low penetrance risk alleles [183]. 
Linkage analysis and genome-wide association studies have enabled the identification of 
several of these alleles, but a majority of these alleles remain to be identified [99, 184-
186]. Emerging research is currently focusing on breast cancer not as a single disease, but 
as an array of diseases associated with varying mechanisms. Different approaches (e.g. 
cell culture studies, animal model based studies, and genome wide association studies) 
are being used to study breast cancer, each with its own advantages and disadvantages 
[157, 187, 188]. 
Technology has advanced leaps and bounds and sequencing costs have declined 
considerably making genome wide association studies (GWAS) a very popular method to 
address genetic variations associated with breast cancer. However, like any method, 
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GWAS have its limitations and drawbacks. One of the basic problems is identifying 
spurious associations caused due to confounding effects of environment and/or genetic 
background [189]. Another problem associated with GWAS is the use and comparison of 
heterogeneous populations. This not only leads to spurious associations, but also hinders 
the identification of single nucleotide variants (SNVs) with smaller effect sizes [190]. 
Associated risk alleles identified with GWAS may nominate candidate genes, but 
identifying the causal genes requires fine mapping and, molecular and mechanistic 
studies. These studies become especially challenging if the SNVs detected fall in gene 
deserts [191, 192]. One way these shortcomings of GWAS might be overcome is by 
studying breast cancer risk alleles using experimental organisms. Rats vary in 
susceptibility to mammary carcinogenesis. These rat models help identify loci associated 
with breast cancer which can be tested in human populations to identify SNVs associated 
with breast cancer risk [193]. The added advantage of using rats is that it offers an 
experimental model to study genetically determined mechanisms associated with breast 
cancer [194]. 
Inbred rat strains that differ in susceptibility to 7,12-Dimethylbenz[a]anthracene 
(DMBA) induced carcinogenesis have been used to identify mammary carcinoma 
susceptibility (Mcs) loci by linkage analysis [172, 173]. Rats are a good model of human 
breast cancer, as rat mammary carcinomas are similar to human breast carcinomas with 
respect to histopathology [195]. The cell of origin of both rat mammary and human breast 
carcinomas is mammary ductal cells [196]. Rat mammary carcinomas are also similar to 
human breast cancers with respect to hormone responsiveness; this is opposed to mouse 
mammary carcinomas, which are usually refractive to hormones [195]. Linkage analysis 
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using the DMBA sensitive Wistar-Furth (WF) strain and DMBA resistant Copenhagen 
(Cop) strain led to the prediction of four Mcs loci (i.e. Mcs1, Mcs2, Mcs3, and Mcs4) 
[172, 173]. In this study, we focused on Mcs3, a predicted Mcs QTL, with two peak 
markers, D1Mit11 and D1Wox6, present on rat chromosome 1 [173]. We have physically 
confirmed Mcs3 and mapped this QTL to a 25.8 MB region on rat chromosome 1. 
Results 
Physical Confirmation and Fine Mapping Mcs3 Using WF.Cop Congenic Rats 
Figure 6 is a congenic map of WF.Cop congenic lines that were used to physically 
confirm and map the location of rat Mcs3 QTL that was predicted by Gould and 
colleagues to exist on rat chromosome 1 [181]. Table 1 contains the DMBA induced 
mammary carcinoma susceptibility phenotypes (mean ± SD mammary tumor number per 
rat) of the congenic lines depicted in Figure 6. The WF.Cop congenic lines A and D 
developed 3.4 ± 2.2 and 2.8 ± 2.3 DMBA-tumors/rat, respectively. A combined group of 
susceptible WF females and WF/WF homozygous genotype littermates from congenic 
lines developed 6.3 ± 3.9 DMBA-induced tumors per rat. The susceptible WF phenotype 
in this study was similar to results previously published by denDekker et al where 
susceptible control WF rats developed 6.3 ± 3.3 tumors per rat upon DMBA induction 
[197]. Lines A and D rats developed significantly less mammary tumors per rat compared 
to the susceptible WF females (Mann-Whitney test post hoc p-values = 0.0208 and 
0.0167, respectively). Reduced susceptibility lines A and D were not different from each 
other with respect to DMBA induced tumor multiplicity (Mann-Whitney test post hoc p-
values = 0.496). Thus, the reduced susceptibility phenotypes of lines A and D physically 
confirmed the Mcs3 locus.
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Figure 6. WF.Cop Congenic Map that Defines the Mcs3 Locus. Figure represents 
varying segments on rat chromosome 1 where Mcs3 was predicted to be located and 
congenic lines that were used to map this locus. On the axis, horizontal lines represent 
informative markers that were used to distinguish the WF genotype from the Cop 
genotype. Superscript letters indicate which line the respective line was derived from. 
Red bars represent Cop alleles in congenic lines with a resistant phenotype, yellow bars 
represent congenic lines with a susceptible phenotype, and grey bars represent segments 
of unknown recombination where the genotype wasn’t determined.
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Table 1. Summary of Mammary Carcinoma Susceptibility Phenotype of WF.Cop 
Congenic Lines Used to Map the Mcs3 Locus 
 WF.Cop congenic lines  














Mean (SD) Mammary 
Carcinomas per Rat 
3.4 (2.2) 2.8 (2.3) 6.6 (3.4) 8.1 (3.4) 6.3 (3.9) 
N 30 19 25 29 12 
p-value 
2
 0.010 0.008 0.467 0.496  
1
Informative markers that identified the length of the Cop Chr1 segment 
introgressed onto a susceptible WF genetic background. 
2
p-values are obtained by performing Mann-Whitney nonparametric post hoc tests 
and comparing each phenotype to control WF phenotype after a statistically significant 
Kruskal-Wallis test of p-value  0.0125. 
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Congenic lines E and G developed 6.6 ± 3.4 and 8.1 ± 3.4 mammary tumors per 
rat, respectively. Lines E and G did not differ in tumor multiplicity compared to 
susceptible WF rats (Mann-Whitney test post hoc p-values = 0.467677 and 0.496 
respectively). Lines E and G phenotypes were not different when compared with each 
other (Mann-Whitney test post hoc p-values = 0.496). The congenic segment overlap 
between lines that contain at least one independently acting allele (A and D), and the 
overlap and non-overlap of these lines with congenic line segments that do not contain 
independently acting alleles (E and G) can be used to delimit QTL intervals. Congenic 
Mcs3-asscociated reduced-susceptibility lines A and D overlapped each other minimally 
from markers D1Rat321 to ENSRNOSNP2784267, and maximally from D1Rat 320 to 
ENSRNOSNP2784322 (Figure 6). Susceptible line E overlapped lines A and D from 
ENSRNOSNP2783800 to ENSRNOSNP2784088. Susceptible Line G overlapped 
susceptible line A. These results indicated that the region between ENSRNOSNP2783800 
and ENSRNOSNP2784088 does not contain an independently acting Mcs QTL. Taken 
together, our congenic studies here indicated lines A, D, E and G delimited the Mcs3 
QTL to a 25.8 Mb region on rat chromosome 1 that spans from ENSRNOSNP2784088 to 
ENSRNOSNP2784322 (~25.8 Mb, 138,096,182 – 163,886,079). 
Human Ortholog to Rat Mcs3 Locus 
The Mcs3 locus from ENSRNOSNP2784088 to ENSRNOSNP2784322 was found 
to align to four syntenic regions that are on human chromosomes 11 and 15 as shown in 
table 2. Figure 7 contains known genes at the Mcs3 locus. These genes were identified 





Figure 7. Transcript Map of the Defined Mcs3 Locus. Map shows known and 
predicted transcripts within the defined Mcs3 locus that were annotated on the UCSC 
Rattus norvegicus version 3.4/rn4 Genome Browser. The X axis represents the Mcs3 
locus which is present on rat chromosome 1 from genetic makers D1 Rat350 to D1 
Rat277. The marker position is represented by labeled tick marks on the X-axis. The 
vertical lines demarcate the maximal Mcs3 locus. The transcripts are shown by their 
NCBI gene symbols at their approximate genomic positions. 
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Table 2. Loci on Human Chromosome That are Syntenic to the Rat Mcs3 Locus on 
Chromosome 1 from ENSRNOSNP2784088 to ENSRNOSNP2784322. 
Information regarding human loci that are Orthologous to Rat Mcs3 locus 
(Chromosome 1: 138,096,182 – 163,886,079) 
Human chromosome: base 
position 
Percent identity 
between bases (%) 
Percent identity 
between span (%) 
11: 71,626,810 –89,350,902 25.3 63.3 
11: 3,631,069 –6,744,074 2.9 15.7 
15: 80,282,370 –82,577,745 3.6 8.2 
15: 83,803,297 –84,806,774 1.3 3.4 
Position is Rattus norvegicus genome build version 3.4. 
Position is Homo sapiens genome build version hg19. 
  
 44 
Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser 
 
 
Genes Location  Homologues Location
Hdgfrp3 (ENSRNOG00000019740) 1:138098819-138119696 RP11-382A20.3 (ENSG00000166503) 15:83784320-83876770
D4A0X9_RAT (ENSRNOG00000019770) 1:138189345-138202803 BNC1 (ENSG00000169594) 15:83924655-83953466
Sh3gl3 (ENSRNOG00000019776) 1:138398334-138529056 SH3GL3 (ENSG00000140600) 15:84115980-84287495
F1M767_RAT (ENSRNOG00000010840) 1:138563870-138876886 ADAMTSL3 (ENSG00000156218) 15:84322838-84708594
Fam154b (ENSRNOG00000026296) 1:138905988-138920522 FAM154B (ENSG00000188659) 15:82555151-82577271
Eftud1 (ENSRNOG00000032723) 1:138920620-139014913 EFTUD1 (ENSG00000140598) 15:82422571-82555104
D3ZFL6_RAT (ENSRNOG00000025142) 1:139135884-139138449 MEX3B (ENSG00000183496) 15:82334119-82338482
D4ABU9_RAT (ENSRNOG00000036972) 1:139418553-139442493 No homologues
Tmc3 (ENSRNOG00000025088) 1:139842574-139886756 TMC3 (ENSG00000188869) 15:81623558-81666554
Stard5 (ENSRNOG00000025052) 1:139896272-139905625 STARD5 (ENSG00000172345) 15:81601394-81616524
Il16 (ENSRNOG00000011680) 1:139908061-140000146 IL16 (ENSG00000172349) 15:81451916-81605104
RGD1310371 (ENSRNOG00000012301) 1:140036328-140061890 C15orf26 (ENSG00000156206) 15:81299374-81441516
Mesdc1 (ENSRNOG00000012349) 1:140157974-140159062 MESDC1 (ENSG00000140406) 15:81293295-81296342
Mesdc2 (ENSRNOG00000012366) 1:140167851-140173514 MESDC2 (ENSG00000117899) 15:81239667-81282219
RGD1305254 (ENSRNOG00000012442) 1:140203040-140270662 KIAA1199 (ENSG00000103888) 15:81071684-81244117
Fam108c1 (ENSRNOG00000012683) 1:140382431-140423393 FAM108C1 (ENSG00000136379) 15:80972025-81047962
Arnt2 (ENSRNOG00000013017) 1:140535823-140693148 ARNT2 (ENSG00000172379) 15:80696692-80890278
FAAA_RAT (ENSRNOG00000013223) 1:140851979-140876087 FAH (ENSG00000103876) 15:80444832-80479288
Zfand6 (ENSRNOG00000013506) 1:140885729-140960486 ZFAND6 (ENSG00000086666) 15:80351910-80430735
Olr10 (ENSRNOG00000029100) 1:141151954-141152901 No homologues
Olr11 (ENSRNOG00000032046) 1:141497719-141498669 No homologues
Vom2r40 (ENSRNOG00000030229) 1:141602289-141721711 No homologues
Vom2r41 (ENSRNOG00000028804) 1:141861806-141914331 No homologues
Vom2r42 (ENSRNOG00000043159) 1:142010227-142055405 No homologues
Vom2r43 (ENSRNOG00000013563) 1:142267794-142290322 No homologues
Olr12 (ENSRNOG00000033009) 1:142339329-142340252 OR13G1 (ENSG00000197437) 1:247835320-247836365
Olr13 (ENSRNOG00000032371) 1:142363442-142364368 OR6F1 (ENSG00000169214) 1:247875045-247876105
Olr14 (ENSRNOG00000030565) 1:142393184-142394125 OR14A2 (ENSG00000241128) 1:247886401-247887345
Olr16 (ENSRNOG00000031741) 1:142435591-142436541 OR14A2 (ENSG00000241128) 1:247886401-247887345
Olr17 (ENSRNOG00000030774) 1:142443502-142444458 No homologues
Olr19 (ENSRNOG00000032077) 1:142491573-142492532 No homologues
D4A8P2_RAT (ENSRNOG00000024653) 1:142500803-142501792 No homologues
Olr20 (ENSRNOG00000032843) 1:142539267-142540259 No homologues
Olr23 (ENSRNOG00000029907) 1:142677366-142678361 No homologues
Olr24 (ENSRNOG00000031858) 1:142710362-142711303 OR14A2 (ENSG00000241128) 1:247886401-247887345
Olr25 (ENSRNOG00000028897) 1:142740112-142741104 No homologues
Olr27 (ENSRNOG00000033105) 1:142782825-142783766 OR14A2 (ENSG00000241128) 1:247886401-247887345
D3ZPM8_RAT (ENSRNOG00000032179) 1:142795102-142800862 No homologues
Olr29 (ENSRNOG00000030176) 1:142819617-142820624 OR14A2 (ENSG00000241128) 1:247886401-247887345
Olr30 (ENSRNOG00000029233) 1:142835594-142836523 No homologues
Olr32 (ENSRNOG00000033463) 1:142871429-142872436 OR14A2 (ENSG00000241128) 1:247886401-247887345
Olr34 (ENSRNOG00000030554) 1:142922930-142923868 No homologues
Folh1 (ENSRNOG00000013770) 1:142936379-143010358 FOLH1 (ENSG00000086205) 11:49168187-49230222
F1M627_RAT (ENSRNOG00000021928) 1:142990978-142991758 No homologues
LOC682236 (ENSRNOG00000033507) 1:143105977-143137062 No homologues
F1M7J6_RAT (ENSRNOG00000028905) 1:143224045-143225319 No homologues
Nox4 (ENSRNOG00000013925) 1:143415816-143603546 NOX4 (ENSG00000086991) 11:89057524-89322779
Tyr (ENSRNOG00000016421) 1:143641257-143746315 TYR (ENSG00000077498) 11:88910620-89028908
Grm5 (ENSRNOG00000016429) 1:143863506-144477283 GRM5 (ENSG00000168959) 11:88237744-88799113
Ctsc (ENSRNOG00000016496) 1:144629802-144661183 CTSC (ENSG00000109861) 11:88026773-88070955
Rab38 (ENSRNOG00000016769) 1:144783909-144864574 RAB38 (ENSG00000123892) 11:87846431-87908635
F1M7E7_RAT (ENSRNOG00000031869) 1:144968576-144968944 No homologues
Tmem135 (ENSRNOG00000016815) 1:145664797-145894704 TMEM135 (ENSG00000166575) 11:86748886-87034756
Fzd4 (ENSRNOG00000016848) 1:145953746-145957666 FZD4 (ENSG00000174804) 11:86656721-86666433
Prss23 (ENSRNOG00000017307) 1:146081557-146089928 PRSS23 (ENSG00000150687) 11:86502101-86663886
F1M6N3_RAT (ENSRNOG00000017296) 1:146082484-146082870 No homologues
F1LUQ4_RAT (ENSRNOG00000017311) 1:146313072-146422586 ME3 (ENSG00000151376) 11:86152150-86383678
D4A6D5_RAT (ENSRNOG00000031186) 1:146425722-146426346 No homologues
Rattus norvegicus Homo sapiens
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
 
Genes Location  Homologues Location
D4ADM4_RAT (ENSRNOG00000033733) 1:146430328-146487051 CCDC81 (ENSG00000149201) 11:86085778-86134151
LOC680217 (ENSRNOG00000022941) 1:146506681-146507085 No homologues
LOC293103 (ENSRNOG00000017383) 1:146522015-146545246 C11orf73 (ENSG00000149196) 11:86013253-86056969
Eed (ENSRNOG00000017509) 1:146563964-146591042 EED (ENSG00000074266) 11:85955586-85989781
Picalm (ENSRNOG00000018322) 1:146754045-146834296 PICALM (ENSG00000073921) 11:85668727-85780924
LOC680270 (ENSRNOG00000022808) 1:146869691-146919120 CCDC83 (ENSG00000150676) 11:85566144-85631064
F1LN23_RAT (ENSRNOG00000030776) 1:146977959-147084664 SYTL2 (ENSG00000137501) 11:85405267-85522184
Ccdc89 (ENSRNOG00000022766) 1:147091688-147092949 CCDC89 (ENSG00000179071) 11:85394893-85397320
Crebzf (ENSRNOG00000018987) 1:147124224-147129115 CREBZF (ENSG00000137504) 11:85370752-85393951
Tmem126a (ENSRNOG00000022748) 1:147129335-147137259 TMEM126A (ENSG00000171202) 11:85359011-85367591
Tmem126b (ENSRNOG00000022732) 1:147146187-147158120 TMEM126B (ENSG00000171204) 11:85339629-85347580
Dlg2 (ENSRNOG00000022635) 1:148051658-149274633 DLG2 (ENSG00000150672) 11:83166055-85338966
F1LZX0_RAT (ENSRNOG00000033242) 1:149145746-149173468 No homologues
F1M2B1_RAT (ENSRNOG00000022627) 1:149355092-149356667 RP11-574F21.3 (ENSG00000258465) 1:160187254-160254920
DCAF8 (ENSG00000132716) 1:160185505-160254920
Ccdc90b (ENSRNOG00000009462) 1:149410497-149424047 CCDC90B (ENSG00000137500) 11:82970139-82997450
Ankrd42 (ENSRNOG00000009664) 1:149423846-149468863 ANKRD42 (ENSG00000137494) 11:82904754-82971736
Pcf11 (ENSRNOG00000009891) 1:149475611-149501027 PCF11 (ENSG00000165494) 11:82868030-82898493
Rab30 (ENSRNOG00000010224) 1:149656373-149670208 RAB30 (ENSG00000137502) 11:82684175-82782965
RGD1559690 (ENSRNOG00000022521) 1:149685958-149710264 C11orf82 (ENSG00000165490) 11:82611017-82669319
Prcp (ENSRNOG00000010630) 1:149711289-149763868 PRCP (ENSG00000137509) 11:82534544-82681626
F1M1I2_RAT (ENSRNOG00000023369) 1:149785072-149786082 No homologues
Fam181b (ENSRNOG00000010763) 1:149955641-149957129 FAM181B (ENSG00000182103) 11:82443053-82444906
RGD1561957 (ENSRNOG00000032343) 1:151354250-151354732 No homologues
D4A3T7_RAT (ENSRNOG00000025368) 1:153438818-153439081 No homologues
Odz4 (ENSRNOG00000011151) 1:153808625-154172717 ODZ4 (ENSG00000149256) 11:78363876-79151992
Nars2 (ENSRNOG00000011476) 1:154216134-154329582 NARS2 (ENSG00000137513) 11:78147007-78285919
Gab2 (ENSRNOG00000011882) 1:154348781-154544906 GAB2 (ENSG00000033327) 11:77926343-78129394
D4AAA3_RAT (ENSRNOG00000024961) 1:154549903-154565904 USP35 (ENSG00000118369) 11:77899858-77925757
Kctd21 (ENSRNOG00000024793) 1:154587686-154588566 KCTD21 (ENSG00000188997) 11:77882295-77899868
Alg8 (ENSRNOG00000012292) 1:154607442-154628226 ALG8 (ENSG00000159063) 11:77811982-77850706
Ndufc2 (ENSRNOG00000012383) 1:154635889-154642111 NDUFC2 (ENSG00000151366) 11:77779350-77791265
NDUFC2-KCTD14 (ENSG00000259112)11:77728017-77790911
Thrsp (ENSRNOG00000012404) 1:154647341-154651663 THRSP (ENSG00000151365) 11:77774907-77779397
D4AAA7_RAT (ENSRNOG00000036873) 1:154660657-154661255 PRDX2 (ENSG00000167815) 19:12907634-12912694
Kctd14 (ENSRNOG00000012494) 1:154684785-154690800 KCTD14 (ENSG00000151364) 11:77726761-77757237
D3ZZQ6_RAT (ENSRNOG00000012552) 1:154714605-154778361 INTS4 (ENSG00000149262) 11:77589766-77705724
RGD1561459 (ENSRNOG00000012584) 1:154786525-154800839 C11orf67 (ENSG00000087884) 11:77532155-77629478
D3ZGQ8_RAT (ENSRNOG00000024194) 1:154817662-154935717 RSF1 (ENSG00000048649) 11:77371041-77532063
Clns1a (ENSRNOG00000012788) 1:154946673-154966945 CLNS1A (ENSG00000074201) 11:77225981-77348850
Aqp11 (ENSRNOG00000013358) 1:154973798-154983989 AQP11 (ENSG00000178301) 11:77300436-77321400
Pak1 (ENSRNOG00000029784) 1:155057622-155174708 PAK1 (ENSG00000149269) 11:77032752-77185680
F1M812_RAT (ENSRNOG00000028470) 1:155199289-155253342 GDPD4 (ENSG00000178795) 11:76927603-77012732
D4AB24_RAT (ENSRNOG00000013641) 1:155292620-155362698 MYO7A (ENSG00000137474) 11:76839310-76926284
Capn5 (ENSRNOG00000014251) 1:155366703-155421183 CAPN5 (ENSG00000149260) 11:76777979-76837201
B3gnt6 (ENSRNOG00000014471) 1:155435459-155440490 B3GNT6 (ENSG00000198488) 11:76745385-76753096
Acer3 (ENSRNOG00000036866) 1:155455466-155509236 ACER3 (ENSG00000078124) 11:76571911-76737841
Tsku (ENSRNOG00000027784) 1:155611070-155622378 TSKU (ENSG00000182704) 11:76493295-76509198
F1M245_RAT (ENSRNOG00000015058) 1:155716478-155747851 No homologues
Lrrc32 (ENSRNOG00000015310) 1:155761334-155771294 LRRC32 (ENSG00000137507) 11:76368568-76381791
D4AC97_RAT (ENSRNOG00000015560) 1:155862045-155931127 C11orf30 (ENSG00000158636) 11:76155967-76264069
Prkrir (ENSRNOG00000015808) 1:155982782-155997548 PRKRIR (ENSG00000137492) 11:76061000-76092015
Wnt11 (ENSRNOG00000015982) 1:156126223-156140802 WNT11 (ENSG00000085741) 11:75897369-75921803
RGD1561870 (ENSRNOG00000042782) 1:156142284-156142592 No homologues
D3ZKE1_RAT (ENSRNOG00000016206) 1:156174285-156435696 UVRAG (ENSG00000198382) 11:75526212-75854239
Dgat2 (ENSRNOG00000016573) 1:156447588-156478740 DGAT2 (ENSG00000062282) 11:75470557-75512579
Mogat2 (ENSRNOG00000027228) 1:156516533-156540899 MOGAT2 (ENSG00000166391) 11:75428864-75444003
Map6 (ENSRNOG00000027204) 1:156592504-156657997 MAP6 (ENSG00000171533) 11:75297963-75380165
Rattus norvegicus Homo sapiens
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
 
Genes Location  Homologues Location
Serpinh1 (ENSRNOG00000016831) 1:156667042-156674221 SERPINH1 (ENSG00000149257) 11:75273101-75283828
B5DF39_RAT (ENSRNOG00000036859) 1:156703241-156794530 GDPD5 (ENSG00000158555) 11:75145685-75236948
Klhl35 (ENSRNOG00000017365) 1:156801077-156806657 KLHL35 (ENSG00000149243) 11:75133438-75141674
Rps3 (ENSRNOG00000017418) 1:156811473-156816770 No homologues
Arrb1 (ENSRNOG00000030404) 1:156871562-156937540 ARRB1 (ENSG00000137486) 11:74975226-75062873
LOC681316 (ENSRNOG00000017922) 1:156958285-156959444 No homologues
Slco2b1 (ENSRNOG00000017976) 1:156992493-157028887 SLCO2B1 (ENSG00000137491) 11:74811608-74917594
Q5RJS1_RAT (ENSRNOG00000018071) 1:157074498-157076449 OR2AT4 (ENSG00000171561) 11:74799758-74800799
Olr36 (ENSRNOG00000030788) 1:157085954-157086934 No homologues
Olr37 (ENSRNOG00000018078) 1:157123043-157124008 No homologues
Neu3 (ENSRNOG00000018106) 1:157172548-157183064 NEU3 (ENSG00000162139) 11:74699179-74729938
Spcs2 (ENSRNOG00000018164) 1:157199447-157217395 SPCS2 (ENSG00000118363) 11:74660292-74690076
F1MAJ1_RAT (ENSRNOG00000026503) 1:157217625-157281411 XRRA1 (ENSG00000166435) 11:74518784-74660245
LOC685009 (ENSRNOG00000026408) 1:157289186-157313991 RNF169 (ENSG00000166439) 11:74459913-74553458
LOC100360934 (ENSRNOG00000018394) 1:157391482-157399282 CHRDL2 (ENSG00000054938) 11:74407474-74442430
Pold3 (ENSRNOG00000018411) 1:157453059-157490563 POLD3 (ENSG00000077514) 11:74204896-74380162
Lipt2 (ENSRNOG00000016906) 1:157538704-157541031 LIPT2 (ENSG00000175536) 11:74202757-74204778
Kcne3 (ENSRNOG00000017054) 1:157558044-157565007 KCNE3 (ENSG00000175538) 11:74165886-74178774
Pgm2l1 (ENSRNOG00000017079) 1:157605906-157655227 PGM2L1 (ENSG00000165434) 11:74041363-74109518
P4ha3 (ENSRNOG00000017118) 1:157663338-157720713 P4HA3 (ENSG00000149380) 11:73946846-74022702
Ppme1 (ENSRNOG00000017227) 1:157725633-157773879 PPME1 (ENSG00000214517) 11:73882144-73965748
D3ZXD6_RAT (ENSRNOG00000017608) 1:157774329-157892686 C2CD3 (ENSG00000168014) 11:73723763-73882255
Ucp3 (ENSRNOG00000017716) 1:157896001-157909606 UCP3 (ENSG00000175564) 11:73711326-73720480
Ucp2 (ENSRNOG00000017854) 1:157922179-157928518 UCP2 (ENSG00000175567) 11:73685712-73694352
Dnajb13 (ENSRNOG00000017975) 1:157931501-157945870 DNAJB13 (ENSG00000187726) 11:73661364-73681411
Chchd8 (ENSRNOG00000025385) 1:157965119-157968347 CHCHD8 (ENSG00000181924) 11:73583712-73588033
Mrpl48 (ENSRNOG00000018042) 1:157979818-158022405 MRPL48 (ENSG00000175581) 11:73498361-73576178
Rab6a (ENSRNOG00000018176) 1:158041088-158080213 RAB6A (ENSG00000175582) 11:73386938-73472182
RAB6C (ENSG00000222014) 2:130737235-130740311
Plekhb1 (ENSRNOG00000018627) 1:158081930-158099517 PLEKHB1 (ENSG00000021300) 11:73357223-73373864
Fam168a (ENSRNOG00000018873) 1:158140473-158287606 FAM168A (ENSG00000054965) 11:73111532-73309234
Relt (ENSRNOG00000025075) 1:158293361-158300581 RELT (ENSG00000054967) 11:73087309-73108519
D4ADZ1_RAT (ENSRNOG00000019192) 1:158316868-158375737 ARHGEF17 (ENSG00000110237) 11:73019334-73080136
P2ry6 (ENSRNOG00000019270) 1:158381128-158406783 P2RY6 (ENSG00000171631) 11:72975550-73009662
P2ry2 (ENSRNOG00000019283) 1:158440062-158446040 P2RY2 (ENSG00000175591) 11:72929343-72947397
Fchsd2 (ENSRNOG00000019319) 1:158548830-158782422 FCHSD2 (ENSG00000137478) 11:72547790-72853306
Q6QI52_RAT (ENSRNOG00000033196) 1:158590389-158593205 No homologues
Atg16l2 (ENSRNOG00000019413) 1:158787779-158800330 ATG16L2 (ENSG00000168010) 11:72525353-72554719
Stard10 (ENSRNOG00000019491) 1:158819970-158845080 STARD10 (ENSG00000214530) 11:72465774-72505213
F1LM60_RAT (ENSRNOG00000019555) 1:158846702-158912163 ARAP1 (ENSG00000186635) 11:72396114-72504644
Pde2a (ENSRNOG00000019560) 1:158921607-159013829 PDE2A (ENSG00000186642) 11:72287185-72385635
Art2 (ENSRNOG00000019687) 1:159055461-159058780 No homologues
F1LXX4_RAT (ENSRNOG00000042674) 1:159116498-159117496 No homologues
Clpb (ENSRNOG00000019693) 1:159126512-159246279 CLPB (ENSG00000162129) 11:72003469-72145692
Phox2a (ENSRNOG00000019706) 1:159273524-159277731 PHOX2A (ENSG00000165462) 11:71950121-71956708
Inppl1 (ENSRNOG00000019730) 1:159278130-159291910 INPPL1 (ENSG00000165458) 11:71934745-71950149
Folr2 (ENSRNOG00000019890) 1:159295773-159300030 FOLR2 (ENSG00000165457) 11:71927645-71932994
Folr1 (ENSRNOG00000019902) 1:159315192-159324141 FOLR1 (ENSG00000110195) 11:71900602-71907345
RGD1311634 (ENSRNOG00000019936) 1:159359110-159362843 C11orf51 (ENSG00000110200) 11:71817424-71823826
Lrtomt (ENSRNOG00000023434) 1:159362010-159364059 LRTOMT (ENSG00000184154) 11:71791382-71821828
MGC72560 (ENSRNOG00000020016) 1:159367471-159373042 LAMTOR1 (ENSG00000149357) 11:71796941-71814433
Lrrc51 (ENSRNOG00000020124) 1:159373973-159393171 No homologues
F1LW91_RAT (ENSRNOG00000000417) 1:159435751-159470959 NUMA1 (ENSG00000137497) 11:71713910-71791739
Il18bp (ENSRNOG00000020150) 1:159471809-159473288 IL18BP (ENSG00000137496) 11:71709587-71716761
Rnf121 (ENSRNOG00000020175) 1:159475046-159542451 RNF121 (ENSG00000137522) 11:71639747-71708643
TRPC2_RAT (ENSRNOG00000020188) 1:159542820-159576982 No homologues
F1M3Z1_RAT (ENSRNOG00000036817) 1:159546441-159547441 No homologues
Art5 (ENSRNOG00000020242) 1:159576991-159586949 ART5 (ENSG00000167311) 11:3659733-3663546
Rattus norvegicus Homo sapiens
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
 
Genes Location  Homologues Location
Art1 (ENSRNOG00000020251) 1:159586246-159590797 ART1 (ENSG00000129744) 11:3666358-3685646
Chrna10 (ENSRNOG00000020293) 1:159590904-159595101 CHRNA10 (ENSG00000129749) 11:3686817-3692614
Nup98 (ENSRNOG00000020347) 1:159598048-159696720 NUP98 (ENSG00000110713) 11:3692313-3819022
Pgap2 (ENSRNOG00000020371) 1:159696920-159722558 PGAP2 (ENSG00000148985) 11:3818954-3847601
Rhog (ENSRNOG00000020393) 1:159724016-159735532 RHOG (ENSG00000177105) 11:3848208-3862213
Stim1 (ENSRNOG00000020425) 1:159761567-159925836 STIM1 (ENSG00000167323) 11:3875757-4114439
Olr40 (ENSRNOG00000018541) 1:160090914-160091975 No homologues
Olr41 (ENSRNOG00000012071) 1:160145884-160146825 OR52B4 (ENSG00000221996) 11:4388493-4389616
Trim21 (ENSRNOG00000018517) 1:160175882-160187661 TRIM21 (ENSG00000132109) 11:4406127-4414926
Olr43 (ENSRNOG00000018514) 1:160208359-160209309 No homologues
Olr44 (ENSRNOG00000018512) 1:160220248-160221195 No homologues
Olr45 (ENSRNOG00000018508) 1:160237160-160238113 OR52K2 (ENSG00000181963) 11:4470525-4471591
Olr46 (ENSRNOG00000018506) 1:160247696-160248640 OR52K1 (ENSG00000196778) 11:4510109-4511138
LOC293190 (ENSRNOG00000018503) 1:160254067-160254579 BCL2L1 (ENSG00000171552) 20:30252255-30311792
Olr47 (ENSRNOG00000018501) 1:160258278-160259237 No homologues
Olr48 (ENSRNOG00000018497) 1:160275366-160276438 OR52M1 (ENSG00000197790) 11:4566421-4567374
Olr49 (ENSRNOG00000015444) 1:160489681-160490646 OR51S1 (ENSG00000176922) 11:4869427-4870514
D3ZYR2_RAT (ENSRNOG00000015432) 1:160503871-160527438 OR51F1 (ENSG00000188069) 11:4790209-4791168
Olr51 (ENSRNOG00000015424) 1:160512753-160513703 OR51F2 (ENSG00000176925) 11:4842551-4843686
Olr53 (ENSRNOG00000031110) 1:160547823-160548767 No homologues
Olr56 (ENSRNOG00000015412) 1:160573393-160574343 OR51C1P (ENSG00000197674) 11:4711988-4713394
Olr57 (ENSRNOG00000015407) 1:160580940-160581884 AC103710.1 (ENSG00000197426) 11:4730835-4731698
Olr59 (ENSRNOG00000018606) 1:160607895-160613802 OR51E2 (ENSG00000167332) 11:4701401-4719084
Olr60 (ENSRNOG00000029206) 1:160626353-160627315 No homologues
Olr61 (ENSRNOG00000033046) 1:160634724-160635686 No homologues
Olr62 (ENSRNOG00000031787) 1:160643870-160644832 No homologues
Olr63 (ENSRNOG00000018551) 1:160647966-160648919 OR51E1 (ENSG00000180785) 11:4664650-4676718
Olr67 (ENSRNOG00000034083) 1:160746318-160747394 OR51A7 (ENSG00000176895) 11:4928600-4965356
Olr68 (ENSRNOG00000015649) 1:160765772-160766740 OR51A7 (ENSG00000176895) 11:4928600-4965356
Olr69 (ENSRNOG00000015657) 1:160771342-160773093 OR51G2 (ENSG00000176893) 11:4935900-4936922
Olr70 (ENSRNOG00000015673) 1:160788683-160789624 OR51G1 (ENSG00000176879) 11:4944531-4945637
F1LWR7_RAT (ENSRNOG00000015681) 1:160805014-160813315 No homologues
Olr74 (ENSRNOG00000015689) 1:160825660-160826619 OR52R1 (ENSG00000176937) 11:4824663-4825847
Olr75 (ENSRNOG00000030860) 1:160833798-160834757 OR51F1 (ENSG00000188069) 11:4790209-4791168
Olr77 (ENSRNOG00000029270) 1:160853088-160854047 OR51F1 (ENSG00000188069) 11:4790209-4791168
Olr78 (ENSRNOG00000015760) 1:160866763-160867710 OR51L1 (ENSG00000176798) 11:5020213-5021160
Olr79 (ENSRNOG00000015764) 1:160873701-160874642 No homologues
Olr80 (ENSRNOG00000015769) 1:160911661-160912676 OR52E2 (ENSG00000176787) 11:5079880-5080857
Olr81 (ENSRNOG00000028970) 1:160922554-160923492 OR52J3 (ENSG00000205495) 11:5067756-5068691
Olr82 (ENSRNOG00000033200) 1:160937940-160938884 No homologues
Olr83 (ENSRNOG00000031586) 1:160955735-160956673 OR52J3 (ENSG00000205495) 11:5067756-5068691
Olr84 (ENSRNOG00000030275) 1:160970408-160971391 No homologues
Olr85 (ENSRNOG00000015785) 1:160977271-160978206 No homologues
Olr86 (ENSRNOG00000021332) 1:161007450-161008388 No homologues
Olr87 (ENSRNOG00000021290) 1:161019428-161020366 No homologues
Olr91 (ENSRNOG00000015804) 1:161076388-161077344 No homologues
Olr92 (ENSRNOG00000015811) 1:161084121-161085065 No homologues
Olr93 (ENSRNOG00000015819) 1:161092784-161093728 No homologues
Olr94 (ENSRNOG00000036811) 1:161099003-161099974 No homologues
Olr95 (ENSRNOG00000036810) 1:161107309-161108253 No homologues
Olr96 (ENSRNOG00000015832) 1:161117890-161118846 No homologues
Olr97 (ENSRNOG00000011001) 1:161128788-161130043 No homologues
Olr98 (ENSRNOG00000033060) 1:161149322-161150269 No homologues
F1LUF0_RAT (ENSRNOG00000043307) 1:161165381-161185205 No homologues
Olr101 (ENSRNOG00000031820) 1:161175882-161176832 No homologues
Olr103 (ENSRNOG00000030169) 1:161204913-161205863 No homologues
Olr104 (ENSRNOG00000015876) 1:161216105-161217064 No homologues
Olr105 (ENSRNOG00000015885) 1:161229983-161230930 No homologues
Rattus norvegicus Homo sapiens
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
 
Genes Location  Homologues Location
Olr106 (ENSRNOG00000015893) 1:161240522-161241493 No homologues
Olr107 (ENSRNOG00000015901) 1:161253006-161254085 No homologues
Olr108 (ENSRNOG00000015909) 1:161270136-161271077 No homologues
Olr109 (ENSRNOG00000015919) 1:161273981-161274934 No homologues
Olr110 (ENSRNOG00000015924) 1:161286481-161287446 No homologues
Olr111 (ENSRNOG00000015926) 1:161318671-161319618 No homologues
Olr112 (ENSRNOG00000015933) 1:161330800-161331762 No homologues
Olr113 (ENSRNOG00000015940) 1:161340241-161341182 No homologues
Olr114 (ENSRNOG00000032357) 1:161347591-161348535 No homologues
Olr115 (ENSRNOG00000031878) 1:161362778-161363731 No homologues
F1M0A2_RAT (ENSRNOG00000015966) 1:161377757-161378526 NRBF2 (ENSG00000148572) 10:64893050-64914783
D3ZMJ6_RAT (ENSRNOG00000042552) 1:161418106-161419072 No homologues
Olr119 (ENSRNOG00000033350) 1:161432556-161433509 OR51B6 (ENSG00000176239) 11:5344961-5373676
Olr120 (ENSRNOG00000031550) 1:161440488-161441432 No homologues
Olr121 (ENSRNOG00000030395) 1:161457068-161458021 No homologues
Olr122 (ENSRNOG00000029978) 1:161468297-161469247 No homologues
F1M2P3_RAT (ENSRNOG00000032984) 1:161482950-161483890 No homologues
Olr124 (ENSRNOG00000016018) 1:161490750-161491697 No homologues
Olr125 (ENSRNOG00000016027) 1:161506536-161507495 No homologues
Olr126 (ENSRNOG00000029612) 1:161520711-161521661 OR52A5 (ENSG00000171944) 11:5152922-5153872
Olr127 (ENSRNOG00000034039) 1:161542787-161543734 OR52A5 (ENSG00000171944) 11:5152922-5153872
Olr128 (ENSRNOG00000016052) 1:161566055-161567017 No homologues
LOC689064 (ENSRNOG00000031230) 1:161578128-161579492 HBD (ENSG00000223609) 11:5253908-5256600
HBB (ENSG00000244734) 11:5246694-5250625
Hbb (ENSRNOG00000033465) 1:161584858-161620198 HBD (ENSG00000223609) 11:5253908-5256600
HBB (ENSG00000244734) 11:5246694-5250625
Hbb-b1 (ENSRNOG00000025510) 1:161590671-161598127 HBD (ENSG00000223609) 11:5253908-5256600
HBB (ENSG00000244734) 11:5246694-5250625
Hbg1 (ENSRNOG00000030879) 1:161640240-161641771 No homologues
Hbe2 (ENSRNOG00000030784) 1:161647651-161649279 No homologues
Hbe1 (ENSRNOG00000029286) 1:161651306-161652708 HBE1 (ENSG00000213931) 11:5289582-5526847
Olr129 (ENSRNOG00000025163) 1:161677418-161678353 No homologues
Olr130 (ENSRNOG00000031983) 1:161687005-161687928 No homologues
Olr131 (ENSRNOG00000030179) 1:161697243-161698166 No homologues
Olr132 (ENSRNOG00000029051) 1:161717426-161718373 OR51B6 (ENSG00000176239) 11:5344961-5373676
Olr135 (ENSRNOG00000043392) 1:161758920-161759858 No homologues
Olr136 (ENSRNOG00000024877) 1:161771509-161772462 OR51J1 (ENSG00000184321) 11:5423827-5424777
LOC499219 (ENSRNOG00000024789) 1:161788384-161794974 No homologues
Olr137 (ENSRNOG00000034041) 1:161796236-161797201 OR51Q1 (ENSG00000167360) 11:5443341-5444436
Olr139 (ENSRNOG00000031147) 1:161825890-161826855 OR51Q1 (ENSG00000167360) 11:5443341-5444436
Olr141 (ENSRNOG00000016946) 1:161856623-161857573 No homologues
Olr142 (ENSRNOG00000016954) 1:161872355-161873299 OR51I1 (ENSG00000167359) 11:5451898-5489943
Olr143 (ENSRNOG00000016964) 1:161883447-161884385 OR51I2 (ENSG00000187918) 11:5474638-5475707
Olr144 (ENSRNOG00000016979) 1:161890517-161891461 No homologues
F1LZ60_RAT (ENSRNOG00000023979) 1:161912324-161913262 No homologues
Olr148 (ENSRNOG00000016993) 1:161948171-161949142 OR52D1 (ENSG00000181609) 11:5509915-5510979
RGD1562433 (ENSRNOG00000036807) 1:161962308-161963840 No homologues
Ubqln3 (ENSRNOG00000023833) 1:161974585-161977032 UBQLN3 (ENSG00000175520) 11:5528530-5531215
Ubqlnl (ENSRNOG00000017016) 1:161985144-161986982 UBQLNL (ENSG00000175518) 11:5535623-5537935
RGD1310717 (ENSRNOG00000017039) 1:161990223-161998056 No homologues
Olr149 (ENSRNOG00000017138) 1:162014526-162015476 OR52H1 (ENSG00000181616) 11:5565719-5566779
Olr150 (ENSRNOG00000017143) 1:162032269-162033207 No homologues
Trim6 (ENSRNOG00000017147) 1:162066157-162072075 TRIM6 (ENSG00000121236) 11:5617339-5634188
D3ZA88_RAT (ENSRNOG00000042686) 1:162086771-162093563 TRIM6-TRIM34 (ENSG00000258588) 11:5617955-5665628
TRIM34 (ENSG00000258659) 11:5617946-5665628
Trim5 (ENSRNOG00000017191) 1:162096454-162113409 TRIM5 (ENSG00000132256) 11:5684425-5959849
F1LV70_RAT (ENSRNOG00000036804) 1:162142545-162143057 No homologues
Trim30 (ENSRNOG00000042947) 1:162173307-162174453 No homologues
Rattus norvegicus Homo sapiens
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
Genes Location  Homologues Location
D4A0Y0_RAT (ENSRNOG00000031202) 1:162183971-162184423 No homologues
D3ZA96_RAT (ENSRNOG00000024179) 1:162195024-162196352 No homologues
Olr152 (ENSRNOG00000017211) 1:162202138-162203079 No homologues
Olr153 (ENSRNOG00000017214) 1:162211898-162212872 No homologues
Olr154 (ENSRNOG00000017218) 1:162225307-162226260 No homologues
Olr156 (ENSRNOG00000017239) 1:162247587-162248513 No homologues
Olr157 (ENSRNOG00000017252) 1:162265829-162267222 No homologues
Olr158 (ENSRNOG00000017261) 1:162286565-162287524 OR56B1 (ENSG00000181023) 11:5757681-5758768
Olr159 (ENSRNOG00000031557) 1:162294975-162295946 No homologues
Olr160 (ENSRNOG00000031490) 1:162309721-162310695 No homologues
Olr161 (ENSRNOG00000029963) 1:162319179-162320138 No homologues
Olr162 (ENSRNOG00000034173) 1:162332962-162333921 No homologues
D3ZLJ1_RAT (ENSRNOG00000032841) 1:162340898-162342106 No homologues
Olr163 (ENSRNOG00000031012) 1:162349312-162350277 No homologues





















Olr164 (ENSRNOG00000033899) 1:162392486-162393451 OR52N1 (ENSG00000181001) 11:5809084-5810046
Olr165 (ENSRNOG00000032268) 1:162420209-162421177 No homologues
Olr168 (ENSRNOG00000029647) 1:162486804-162487763 No homologues
Olr170 (ENSRNOG00000029375) 1:162510151-162511116 OR52N1 (ENSG00000181001) 11:5809084-5810046
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Table 3. List of Genes and Genomic Position in the Rat Mcs3 Locus and in the 
Orthologous Human Region Obtained Using Ensembl Genome Browser (continued) 
 
Position is Rattus norvegicus genome build version 3.4  
Position is Archive EnsEMBL Homo sapiens version 67.37 (GRCh37)
Genes Location  Homologues Location
RP11-1286E23.5 (ENSG00000231396) 4:9212383-9213975
RP11-1286E23.18 (ENSG00000250913)4:9274090-9274640
Olr171 (ENSRNOG00000031652) 1:162563516-162564466 No homologues
Olr172 (ENSRNOG00000030695) 1:162571258-162572214 OR52N2 (ENSG00000180988) 11:5841544-5842578
Olr174 (ENSRNOG00000029040) 1:162590020-162590976 OR52N2 (ENSG00000180988) 11:5841544-5842578
Olr175 (ENSRNOG00000017308) 1:162618317-162619282 OR52N2 (ENSG00000180988) 11:5841544-5842578
Olr176 (ENSRNOG00000032615) 1:162626124-162627080 OR52N2 (ENSG00000180988) 11:5841544-5842578
Olr178 (ENSRNOG00000017331) 1:162681198-162682136 No homologues
Olr179 (ENSRNOG00000033989) 1:162728293-162729231 No homologues
Olr180 (ENSRNOG00000033813) 1:162739521-162740471 OR52E8 (ENSG00000183269) 11:5877904-5878964
OR52E6 (ENSG00000205409) 11:5862158-5863182
Olr181 (ENSRNOG00000033534) 1:162772333-162773271 No homologues
Olr183 (ENSRNOG00000027423) 1:162782725-162783666 No homologues
Olr184 (ENSRNOG00000017341) 1:162793777-162794730 OR52E8 (ENSG00000183269) 11:5877904-5878964
OR52E6 (ENSG00000205409) 11:5862158-5863182
Olr185 (ENSRNOG00000017344) 1:162803635-162804588 No homologues
Olr186 (ENSRNOG00000033218) 1:162810227-162811168 No homologues
Olr188 (ENSRNOG00000017351) 1:162835732-162836670 OR52E4 (ENSG00000180974) 11:5905501-5906527
Olr189 (ENSRNOG00000031357) 1:162843036-162843977 No homologues
Olr190 (ENSRNOG00000017357) 1:162857313-162858260 OR56A3 (ENSG00000184478) 11:5968570-5969591
LOC100362148 (ENSRNOG00000017362) 1:162862402-162864364 No homologues
Olr192 (ENSRNOG00000017366) 1:162881824-162882774 No homologues
Olr193 (ENSRNOG00000030947) 1:162895667-162896718 No homologues
Olr194 (ENSRNOG00000029946) 1:162927245-162928195 OR52L1 (ENSG00000183313) 11:6007122-6008215
Olr196 (ENSRNOG00000033931) 1:162966355-162967305 OR52L1 (ENSG00000183313) 11:6007122-6008215
Olr197 (ENSRNOG00000017379) 1:162986552-162987505 No homologues
Olr198 (ENSRNOG00000032010) 1:163004734-163005699 AC111177.1 (ENSG00000180913) 11:6149840-6150706
Olr199 (ENSRNOG00000029755) 1:163021101-163022051 AC111177.1 (ENSG00000180913) 11:6149840-6150706
Olr200 (ENSRNOG00000029155) 1:163042743-163043708 AC111177.1 (ENSG00000180913) 11:6149840-6150706
Olr201 (ENSRNOG00000017387) 1:163069885-163070844 AC022762.1 (ENSG00000180909) 11:6173006-6173818
Olr202 (ENSRNOG00000025819) 1:163080521-163081489 OR52B2 (ENSG00000255307) 11:6190560-6191638
RGD1561034 (ENSRNOG00000030818) 1:163107431-163110605 C11orf42 (ENSG00000180878) 11:6226796-6232362
Fam160a2 (ENSRNOG00000017408) 1:163110928-163133590 FAM160A2 (ENSG00000051009) 11:6232565-6255941
Cnga4 (ENSRNOG00000017609) 1:163137544-163141556 CNGA4 (ENSG00000132259) 11:6255995-6265659
Cckbr (ENSRNOG00000017679) 1:163156914-163166969 CCKBR (ENSG00000110148) 11:6280966-6293357
Prkcdbp (ENSRNOG00000017914) 1:163212922-163214511 PRKCDBP (ENSG00000170955) 11:6340176-6341877
Smpd1 (ENSRNOG00000017977) 1:163278970-163282812 SMPD1 (ENSG00000166311) 11:6411655-6416228
Apbb1 (ENSRNOG00000018020) 1:163282918-163299333 APBB1 (ENSG00000166313) 11:6416354-6440644
Hpx (ENSRNOG00000018257) 1:163319509-163327017 HPX (ENSG00000110169) 11:6452279-6463847
Trim3 (ENSRNOG00000018356) 1:163331603-163362846 TRIM3 (ENSG00000110171) 11:6469843-6495689
Arfip2 (ENSRNOG00000018440) 1:163364861-163369542 ARFIP2 (ENSG00000132254) 11:6496910-6502666
TIM9B_RAT (ENSRNOG00000018654) 1:163369752-163372576 FXC1 (ENSG00000132286) 11:6502677-6530208
F1M5X6_RAT (ENSRNOG00000043327) 1:163380016-163420661 No homologues
D4A4C1_RAT (ENSRNOG00000033327) 1:163433572-163436909 DNHD1 (ENSG00000179532) 11:6518490-6593257
Dnhd1 (ENSRNOG00000043240) 1:163462348-163467223 DNHD1 (ENSG00000179532) 11:6518490-6593257
Rrp8 (ENSRNOG00000018766) 1:163477030-163481051 RRP8 (ENSG00000132275) 11:6616305-6624850
Ilk (ENSRNOG00000018993) 1:163481299-163487550 ILK (ENSG00000166333) 11:6624961-6632102
Taf10 (ENSRNOG00000019178) 1:163487518-163488786 TAF10 (ENSG00000166337) 11:6627526-6633898
Tpp1 (ENSRNOG00000019212) 1:163490393-163496526 TPP1 (ENSG00000166340) 11:6634000-6640692
Dchs1 (ENSRNOG00000031643) 1:163497340-163517091 DCHS1 (ENSG00000166341) 11:6642554-6677085
RM17_RAT (ENSRNOG00000019497) 1:163554719-163556345 MRPL17 (ENSG00000158042) 11:6702013-6704632
D4A3E9_RAT (ENSRNOG00000042713) 1:163589107-163590165 No homologues
RGD1308274 (ENSRNOG00000029048) 1:163590802-163593777 No homologues
D3ZNN6_RAT (ENSRNOG00000042725) 1:163594662-163595836 No homologues
D3ZJQ9_RAT (ENSRNOG00000042292) 1:163596557-163598317 No homologues
D3Z9P7_RAT (ENSRNOG00000042759) 1:163695070-163696128 No homologues
F1LZ18_RAT (ENSRNOG00000019521) 1:163696150-163696605 No homologues
F1LV81_RAT (ENSRNOG00000036793) 1:163767761-163768429 ATMIN (ENSG00000166454) 16:81069452-81080963
Olr203 (ENSRNOG00000032322) 1:163776673-163777620 No homologues
Olr204 (ENSRNOG00000034133) 1:163833782-163834729 No homologues
Olr205 (ENSRNOG00000029697) 1:163874449-163875399 No homologues
Rattus norvegicus Homo sapiens
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Ensemble genome browser was used to generate table 3. Table 3 lists known 
genes at the rat Mcs3 locus and human orthologous loci. Public databases and published 
literature were searched to identify genes at the Mcs3 human orthologous loci associated 
with breast cancer. The cancer portal of Rat Genome Database was used to data mine 
genes associated with breast cancer. We found three genes within the rat Mcs3 locus 
and/or the human orthologous loci associated with breast carcinomas. Table 4 lists these 
genes and known functions. Among these genes, Pak1, Ilk and Il18bp are common to 
both humans and rats. 
Discussion 
The focus of this study was aligned toward providing information regarding the 
genetic aspect of human breast cancer by using rat mammary carcinoma as a model. By 
physically confirming and mapping rat Mcs3, a previously predicted mammary 
carcinoma susceptibility locus, we sought to develop genetic strains to better understand 
the genetic contribution associated with human breast cancer susceptibility, and 
eventually discover the underlying mechanism associated with breast carcinogenesis. In 
this study, Mcs3 was physically confirmed and mapped to a 25.8 Mb region on rat 
chromosome 1 using congenic lines. The Cop Mcs3 allele was found to reduce the 
mammary carcinoma susceptibility phenotype associated with the WF strain by 51% 
when homozygous. In the previous study, that predicted the Mcs3 QTL, one Cop allele at 
the Mcs3 QTL was predicted to reduce 
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Table 4. List of Genes Associated with Breast Cancer and Genomic Position in the 
Rat Mcs3 Locus and in the Orthologous Human Region 
 
Position is Rattus norvegicus genome build version 3.4.  
Position is Homo sapiens genome build version hg19. 
This table displays the position of genes within the human and rat genomes. It also shows 
the Gene symbol and gene name. 
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mammary carcinoma susceptibility by 42% in female rats that were heterozygous at the 
Mcs3 locus [173]. We did not test mammary carcinoma susceptibility in Mcs3 
heterozygous congenic rats. The previous study was performed on F2 and rats from two 
successive backcross generations. The difference in the susceptibility between the two 
studies might be explained by either a possible degree of dominance of the Cop allele at 
the Mcs3 locus, or by background Cop alleles potentially present in the females included 
in the linkage analysis. In this study, Mcs3 was mapped to a 25.8 Mb region on rat 
chromosome 1 between markers ENSRNOSNP2784088 to ENSRNOSNP2784322 (~25.8 
Mb, 138,096,182 – 163,886,079). This region is distal to the predicted Mcs3 peak QTL 
markers D1Mit11 and D1Wox6. This is not the first time that a Mcs locus has been 
physically confirmed outside the predicted QTL interval. Both Mcs1b and Mcs1c are 
beyond the predicted Mcs1 QTL interval [181, 197]. 
Different segments of the rat Mcs3 locus aligned to 4 human loci that were on 
chromosomes 11 and 15, which are shown in table 2. Altogether, the rat and human 
regions contained 3 annotated genes that have been shown to associate with breast 
cancer, namely serine/threonine-protein kinase PAK 1 (PAK1), integrin-linked protein 
kinase (ILK) and, interleukin-18-binding protein (IL18BP). Serine/threonine-protein 
kinase PAK 1 (PAK1) downstream pathways play an important role in development and 
maintenance of metastatic phenotypes in breast cancer cells [198]. PAK1 was also shown 
to be a predictor of recurrence and tamoxifen resistance in post-menopausal breast cancer 
[199]. Integrin-linked protein kinase (ILK) may be an important marker since increased 
expression of ILK is associated with aggressive progression and poor prognosis of breast 
cancer [200]. ILK was shown to regulate γ-secretase-mediated Notch1 activation in IL-6 
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induced breast cancer stem cells [201]. Interleukin-18-binding protein (IL18BP) regulates 
the activity of interleukin 18. IL-18 expression is significantly higher in malignant breast 
tumor tissue as compared to breast tissue of patients with benign breast disease [202]. 
Another study suggests IL-18 enhances breast cancer cell migration [203]. 
We conclude that the predicted Mcs3 locus has been physically confirmed and 
mapped to a 25.8 Mb region on the rat chromosome 1. Our analysis suggests that there 
are at least three potential candidate genes located at the rat and orthologous human Mcs3 
genomic region. The rat Mcs3 congenic lines developed will be useful tools to identify 
Mcs3 candidate genes and study mechanisms underlying breast cancer genetic 
susceptibility. 
Materials and Methods 
Congenic Breeding and Genotyping 
Congenic lines were generated using methods previously described [175]. Briefly, 
rats with selected Cop chromosome 1 segments from the predicted Mcs3 QTL were 
introgressed onto a WF/NHsd genetic background. Congenic rat lines were maintained in 
an Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC) approved facility on a 12-hour light/dark cycle and provided LabDiet 5001 
Rodent Diet (PMI Nutrition International) and water ad libitum. All animal protocols 
were approved by the University of Louisville Animal Care and Use Committee 
(Louisville, KY). Information for genetic markers defining ends of COP alleles carried by 
each congenic line A, D, E and G were available at the UCSC Genome Browser 
(www.genome.ucsc.edu), Rat Genome Database (http://rgd.mcw.edu/), or Table 5. 
Animals were genotyped as described in [175]. Briefly, tail clips were used for DNA 
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extraction and genotyping. Five to eight days after birth, the rats were toe tattooed and 
tail clipped. The DNA was extracted to test the genotype at a given locus. Polymorphic 
micro-satellite markers that vary between the two strains were selected and were used to 
PCR amplify the variable region of genomic DNA. The amplified DNA was run on a 3% 
high resolution agarose gel. After the run was complete, the gel was stained in SYBR 
Gold and scanned on a Typhoon scanner. Visible bands were analyzed using 
homozygous Cop and WF, and F1 DNA (heterozygous) as controls. For regions with low 
density of polymorphic STS markers, informative SNP that were polymorphic between 
Cop and WF rats were identified using SNPlotyper tool on Rat Genome Database 
(http://rgd.mcw.edu/).  Phenotyped rat DNA were sequenced to identify the genotype.  
Information for SNP genetic markers defining ends of COP alleles carried by each 
congenic line A and E used for sequencing are available in Table 5.
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Table 5. Primer Sequences for Microsatellites in 25.8 Mb Region of Mcs3 Locus 
D1Rat27 STS GGGCAAGCAAAGTACATGGT TCTCTCCAGCTGCAGGATTT 90282041-90282193
D1Mit30 STS TGTCTTGGCCTCTGATTTCA TGCTGTGTGGACGGAGATAA 94473941-94474122
D1Rat214 STS GATTTTCAATCTTTTAGCAAGCA TTTCAGTGACAACCAGGCTG 100034565-100034664
D1Mit11 STS ATAAGCCAGCCCCCATTC CCTACTGAAAGTGAAATGTCTGG 102532147-102532417
D1Rat32 STS TGAGCCATTGAGTTGTGAGC TGTTTTCCAAATGAAGCGTG 112148734-112149024
D1Rat381 STS TCAAAAGGCTAAGGCAGGAA AGACAAAAATGGAGGCCTCA 115368982-115369185
D1Rat320 STS CTCCACATGCACAGGCATAT CTCCTAAAGGTCCCATTGCA 119536685-119536913
D1Rat321 STS TGCACCAAATTTTCTATTCCA ACATTTGCCTTTTTGGACAT 127965057-127965205
D1Rat36 STS TTCCTGGGGTACTCCCAC TTCCTCTCCTTCAACTCCTCC 128874535-128874670
D1Wo x6 STS CCCCATCTATCTATCCAACGG CTCTGGGATGCTTTGTGAAGG 131956600-131956825
D1Rat382 STS GGCCGAATGCTTTCAATAGA GGCATACATGCTCAAACTGC 132558148-132558270
D1Rat350 STS CCAGATGAAGGCTGATGGAC ACACGGTATTCAATCAGCCC 135620323-135620477
D1Rat173 STS GATCCCTTGACAAGCATGGT GATGGAGGCAGTTTTTCCAA 145283364-145283529
D1Mgh8 STS CCTCTGGATTCTGCCAGAAG TTTCAAATGTACAGGCTGAAACA 156124625-156124741
D1Rat277 STS TCTGGTCTTTACATGTATGTGCA TTCACATCAGTTTTGGCCAC 164875097-164875292
D1Rat243 STS TCAACTCCCAGGGATTGTTC CCCTGCTCTAACCAGCAGTC 172072626-172072864
D1Rat65 STS TGAAGGAGAGCCAGGAATTG   CAGTCTGGGGGTAAGCAAGA 184879920-184880048




GCCCGTCTCCACTTCT 95200769  C/T CC TT
ENSRNOSNP 2783800 
SNP GGAGTCTGGGCACTGT ACACCCAGCTAGCAGG 99077826  T/A TT AA
ENSRNOSNP 2784076 
SNP GTGAGCAGCTGTTGGG GGGAACTCACACCGGA 137304344  T/C TT CC
ENSRNOSNP 2784088 
SNP AGTATCTGCCCGGTGG GGCAAACCGTCCTGAAA 138096182  G/A AA GG
ENSRNOSNP 2784133 
SNP TGCTTCGCCTTAACCTG TGCATGTCAGAAGGGAGA 143556969  G/A GG AA
ENSRNOSNP 2784267 
SNP TGACCTCCGTGCTACC ACCTGGTGTCGCTTCA 158009944  T/A AA TT
ENSRNOSNP 2784322 
SNP AACGGGCCAATGGAATG CCACCAGCCCCTAAGA 163886079  G/T GG TT
ENSRNOSNP 2784324 
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Female congenic and WF/HSd (Harlan) rats were intubated with a single dose of 
DMBA (65 mg DMBA/kg body mass) in sesame oil at 50-55 days of age. Mammary 
carcinomas ≥ 3 × 3mm were counted at 15 weeks post-treatment.  
Statistical Analysis 
Mammary carcinoma multiplicity data were analyzed and congenic rat 
phenotypes were compared to that of susceptible WF/NHsd controls. Mammary 
carcinoma multiplicity phenotypes for more than two groups were compared using 
Kruskal-Wallis nonparametric test. If this test was statistically significant (p value  
0.05), then each group was compared to the WF/NHsd control group by performing 
multiple Mann-Whitney nonparametric tests. A p value of  0.05 was considered to be 
significant.  
Comparative Genomics 
The human orthologous region and transcripts mapping to the rat Mcs3 locus 
were identified using the Rat Genome Database, UCSC Genome Browser and the 
Ensembl Genome Browser. The Rattus norvegicus reference genome sequence version 
3.4/rn4 and Homo sapiens version GRCh37/hg19 were used. The percent of sequence 
identity between the rat and the human region of interest was identified using the 




ASSESSING CONGENIC LINE 1B-11 FOR MCS1B ASSOCIATED PHENOTYPE 
Introduction 
This chapter focuses on rat mammary carcinoma susceptibility locus Mcs1b, 
which was identified from the fine mapping of Mcs1 [181]. Mcs1 is a quantitative trait 
locus (QTL) identified by linkage analysis of DMBA sensitive Wistar-Furth (WF) strain 
and DMBA resistant Copenhagen (Cop) strain [181]. To genetically map the Mcs1 locus, 
WF and Cop rats were bred to generate (WF x Cop) F1 rats. F1 rats were bred with WF 
rats to generate backcross (BC1) rats. BC1 rats were analyzed for linkage between 
polymorphic microsatellite markers and susceptibility to DMBA induced carcinogenesis, 
which was measured by tumor number. The Mcs1 locus was identified on the proximal 
end of rat chromosome 2. The Cop allele at the Mcs1 locus was predicted to reduce 
DMBA induced rat mammary carcinoma susceptibility [172]. In an extension of this 
study, BC1 rats were further backcrossed to generate BC2 rats and F1 rats were crossed 
with each other to generate F2 rats. Linkage analysis, performed in these rats, physically 
confirmed the locus and also confirmed that the Cop allele at the Mcs1 locus reduces 
DMBA induced mammary carcinoma susceptibility [173]. 
The Mcs1b locus was identified by phenotyping Mcs1 congenic rats with varying 
lengths of Cop allele across the Mcs1 locus on a WF genetic background. These rats were 
given a single dose of DMBA at fifty to fifty five days of age and tumor number was 
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counted at fifteen weeks post DMBA administration. This led to the identification of the 
Mcs1a, Mcs1b, and Mcs1c loci. The Cop allele at the Mcs1b locus was identified to 
reduce DMBA induced mammary carcinoma susceptibility [173]. A recent study by 
denDekker et al. from our lab used Mcs1b congenic rats to define this locus to a 1.8 Mb 
region of rat chromosome 2 [137]. The authors performed mammary gland transplant 
assays in which mammary glands from the susceptible or resistant rats were transplanted 
onto the back fat pads of rats with either a susceptible or resistant genotype. These rats 
were then given a single dose of DMBA and tumor outcome was assessed post DMBA 
administration. The results of this experiment showed that irrespective of the recipient 
genotype, the grafts were tumor positive if the donor rat was of the susceptible genotype 
[137]. Thus, Mcs1b acts in a mammary gland autonomous manner. The authors then 
sequenced the open reading frames of genes present in the Mcs1b locus in the WF and 
Mcs1b congenic rats. No differences were identified in the protein coding region 
suggesting that Mcs1b locus could potentially function by controlling non protein coding 
regions and differentially regulating gene expression between the two genotypes. Mcs1b 
gene transcript levels were measured in WF and Mcs1b congenic rats. The authors found 
that Map3k1, Gpbp1, Mier3 were differentially expressed between the two genotypes 
without DMBA exposure, but only Mier3 was differentially expressed between the two 
genotypes with DMBA. Map3k1, Gpbp1, Mier3 transcript levels were found to be lower 
for the candidate genes in the Mcs1b resistant rats compared to the susceptible WF rats. 
[137]. Tumor expression levels of Map3k1, Gpbp1, Il6st and Mier3 was tested. The 
authors found that Mier3 was more highly expressed in tumors as compared to disease 
free mammary tissue [137]. Lastly, it was also noted that Mcs1b female rats had a higher 
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body weight compared to susceptible WF female rats when weighed at 12 weeks of age 
[137]. In summary, Mcs1b associated phenotypes include reduced tumor number, lower 
expression levels of Map3k1, Gpbp1, and Mier3 in mammary tissue compared to 
susceptible WF without DMBA exposure, lower expression levels of Mier3 in mammary 
tissue compared to susceptible WF with DMBA exposure and higher Mier3 expression in 
mammary tumors compared to adjacent disease free mammary tissue. 
It is worth noting that Mcs1b heterozygous congenic rats tested by Haag et al. 
developed an average of 7.6 tumors/rat [181]; whereas, Mcs1b heterozygous congenic 
rats tested by denDekker et al. developed around 5.5 tumors/rat [137]. This discrepancy 
in number of tumors developed by rats that are heterozygous Cop at the Mcs1b locus, 
observed in two different studies, could be due to the difference in the lengths of the 
congenic segment contained in the congenic lines tested; and thus, may be indicative of a 
complex genetic interaction within the Mcs1b locus. To test this hypothesis and delimit 
Mcs1b to the narrowest possible interval, it is essential to continue fine mapping the 
Mcs1b locus by phenotyping Mcs1b congenic lines with shorter Cop alleles. One such 
recombinant generated is congenic line 1b-11 which is shown in figure 8. It was 
generated by backcrossing congenic line T to the parental WF strain. Congenic line 1b-11 
has a Cop allele which spans the distal end of the Mcs1b locus, which was present in the 
Mcs1b rats tested by Haag et al., but was only partially present in the Mcs1b rats tested 
by denDekker et al. Thus, line 1b-11 is a good candidate to test the hypothesis that the 
Mcs1b locus might interact with a distal locus. To test this possibility, congenic line 1b-
11 will be investigated for Mcs1b associated phenotypes. Tumor multiplicity post DMBA 













Figure 8. WF.Cop Congenic Map that defines the Mcs1b Line 1b-11. Figure 
represents varying segments on rat chromosome 2 where Mcs1b was predicted to be 
located and congenic lines that were used to fine-map this locus. On the X axis, blue lines 
represent informative microsatellite markers, red lines represent informative SNPs, and 
green lines represent informative indels. Brown bars represent Cop alleles in congenic 
lines with a resistant phenotype, white bars represent congenic lines with a unknown 
phenotype, and grey bars represent a potential area of recombination where the genotype 
isn’t determined. The horizontal blue bar represents the orthologous region to human 
5q11.2 breast cancer risk (BRCR) associated haplotype block. 
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levels in mammary tumors will be compared to adjacent disease free mammary tissue. 
Mier3, Map3k1, Gpbp1 and Il6st expression levels in mammary gland will be compared 
between 1b-11 and WF females at 12 weeks of age with DMBA and without DMBA 
exposure. Body weights of 1b-11 rats will also be compared to that of WF rats at 12 
weeks of age. The goal of this aim was to narrow the Mcs1b QTL interval and potentially 
identify genetic interactions with another locus. 
Results 
Analysis of Congenic Line 1b-11 Set Ups 
Generating Rats That Were Heterozygous Cop at the 1b-11 Locus 
Initially, there was one fertile male rat that was homozygous at the 1b-11 locus. 
This male was backcrossed with susceptible WF female rats. Table 6 shows that the 
litters (N17 generation) obtained were heterozygous at the 1b-11 locus. The backcross 
was successful with eight out of the eleven set ups produced litters (72% of set ups). The 
litters were comprised of a total of 12 males and 18 females, all of which were 
heterozygous at the 1b-11 locus. These heterozygous rats were inbred in an attempt to fix 
this line and obtain female rats that were homozygous Cop at the 1b-11 locus. 
Generating Rat That Were Homozygous Cop at the 1b-11 Locus 
Rats that were heterozygous at the 1b-11 locus (N17 generation) were set up to 
generate rats that were homozygous Cop at the 1b-11 locus (Table 6). Out of 41 different 
set ups only nine (22% of set ups) produced litters (N17F1 generation). There were a total 
of 22 males and 28 females. N17F1 rats that were homozygous Cop at the 1b-11 locus 
were set up with rats that were heterozygous Cop at the 1b-11 locus to produce the next 
generation (N17F2). Fourteen out of thirty five set ups (40% of set ups) generated litter. 
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Table 6. Analysis of Congenic Lines 1b-11 and Mcs3 Line D Set Ups  
 
Table provides the number of Mcs1b line 1b-11 and Mcs3 line D breeding pairs 
set up and the number of set ups that generated litters. It is further broken down to the 
number of males and females that the litters together contained. The last column is the 





Breeding Pairs Litters Male pups Female pups
Set ups that 
produced litters 
N17 Mcs1b 1b-11 11 8 12 18 72.73
N17F1 Mcs1b 1b-11 41 9 22 28 21.95
N17F2 Mcs1b 1b-11 35 14 16 25 40.00
N17F3 Mcs1b 1b-11 32 3 9.38
N10F4 Mcs3 Line D 10 5 14 17 50.00
N10F5 Mcs3 Line D 8 2 3 3 25.00
N10F6 Mcs3 Line D 9 4 5 5 44.44
N10F7 Mcs3 Line D 11 5 10 10 45.45
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There were a total of 16 males and 25 females. To generate female rats that were 
homozygous Cop at the 1b-11 locus to use in designed experiments male rats and female 
rats that were homozygous Cop at the 1b-11 locus (N17F3 generation). In this case only 
three of the thirty-two setups generated litters (9% of set ups). At this point, a decision 
was made to stop breeding congenic line 1b-11 since it was not generating enough litters. 
Analysis of Mcs3 Congenic Line D Set Ups 
Generating Rats That Were Homozygous Cop at the Mcs3 Line D Locus 
Rats that were homozygous Cop at the Mcs3 line D locus (N10F3 generation) 
were set up to generate the N10F4 generation (Table 6). Out of 10 different set ups, five 
(50% of set ups) produced litters. There were a total of 14 males and 17 females. Since 
all the rats that were set up were homozygous Cop at the Mcs3 Line D locus all Mcs3 line 
D litters generated were also homozygous Cop at the Mcs3 Line D locus. N10F4 rats 
were set up with each other to produce the next generation (N10F5). Two out of eight set 
ups (25% of set ups) generated litter. There were a total of 3 males and 3 females. N10F5 
rats were set up to produce the next generation (N10F6). Four out of nine set ups (44% of 
set ups) generated litter. There were a total of 5 males and 5 females. Like the previous 
three generations the N10F6 generation also bred successfully to generate litters. N10F6 
rats were set up with each other to produce the next generation (N10F7). Five out of 
eleven set ups (45% of set ups) generated litter. There were a total of 10 males and 10 
females. 
Discussion 
The goal of this specific aim was to narrow the Mcs1b locus and identify possible 
complex genetic interactions within the locus. To achieve this goal; congenic line 1b-11 
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rats were needed. However, congenic line 1b-11 did not breed successfully. Mcs3 
congenic line D breeding is also analyzed to display that congenic line 1b-11 was 
breeding poorly. In comparison to congenic line 1b-11, congenic Mcs3 line D always had 
more than 20% of set ups generate litters with larger litter sizes. Congenic line 1b-11 rats 
bred successfully when they were heterozygous Cop at the 1b-11 locus. However, most 
breeders failed to generate litters when rats that were homozygous Cop at the 1b-11 locus 
were bred with each other. In the event that set ups resulted in a litter, the litter either died 
at birth or the female ate her litter soon after. The three litters that did survive had a small 
litter size of 2 to 3 pups each. Thus, it was not feasible to generate litters that were 
homozygous Cop at the 1b-11 locus. 
In general, congenic rats which breed successfully produce a new generation after 
four months. Congenic line 1b-11 rats were slower to breed since fewer rats were fertile 
and took approximately five to six months between generations. The breeding issues 
associated with congenic line 1b-11 rats were noted after eighteen to twenty four months 
of breeding (four generations of breeding). It was still possible to use rats that were 
heterozygous Cop at the 1b-11 locus instead of rats that were homozygous Cop at the 1b-
11 locus to determine if congenic line 1b-11 replicated Mcs1b associated phenotypes. 
However, a larger sample size of these heterozygous rats would be needed to study the 
same phenotypes. Due to the above noted difficulties in breeding congenic line 1b-11 and 
time restrains, the decision was made based on advice from my dissertation committee to 
not continue with this specific aim. 
There are many factors that affect breeding of congenic rats, some of them 
include first mating age, light intensity, stress, pheromones and diet [204-207]. The 
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microenvironment comprises the immediate physical enclosure the animal is in. It 
includes the cage, bedding, food and water supply. The microenvironment is also 
characterized by illumination, noise, vibration, humidity, temperature and the air within 
the cage. The macroenvironment comprises the physical environment of the secondary 
enclosure that houses the primary enclosure. This is the room that contains the rat 
housing cages. The macroenvironment is affected by the design of the animal room, the 
traffic within of animal handlers, animal cages, noise, etc. Although the two 
environments are associated with each other, there are differences between the two. The 
temperature, humidity and illumination vary appreciably between the macro and 
microenvironments. Identifying the causes that resulted in congenic line 1b-11 not 
producing ample litters is beyond the scope of this project. Future research could be 
directed toward addressing this problem. 
Materials and Methods 
Generating WF.Cop Congenic Line 1b-11 
All animals used for this study were housed within the University of Louisville 
Research Resources Center Animal Facility. All animal protocols were approved by the 
University of Louisville IACUC. 
Line 1b-11 was developed through a backcross of Mcs1b resistant WF.Cop line T 
to WF rats. The resultant pups were genotyped using informative markers. The 
recombinant rat with a Cop allele represented in the congenic line 1b-11 was selected and 
further backcrossed to WF females to expand the line. Rats that are heterozygous Cop at 
the 1b-11 locus were used in brother sister matings to inbreed the line and generate rats 
that were homozygous Cop at the 1b-11 locus.  
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Genotyping 
Pups were tail clipped at five to ten days of age and toe tattooed for within litter 
identification. Genomic DNA was extracted to determine genotypes as described in 
chapter 2. SNPs between the two strains were used for genotyping. DNA was amplified 
using TaqMan genotyping master mix from Life Technologies and primers and probes 
specific for SNP markers. Analysis was performed on StepOne Plus QPCR machine ABI 
using the StepOne software for genotyping Analysis. Informative markers used to 
genotype congenic line 1b-11 are shown in table 7. 
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Table 7. Informative Genetic Markers Used to Genotype Congenic Line 1b-11  






















































































MCS1B CANDIDATE GENE EXPRESSION IN RAT MAMMARY EPITHELIAL 
CELLS 
Introduction 
This chapter focuses on the investigation of mammary epithelial cell populations 
(MECs) contained in congenic Mcs1b rat mammary glands. The rat Mcs1b locus was 
mapped to a 1.8Mb region on rat chromosome 2 using congenic rats with Mcs1b 
Copenhagen (Cop) alleles on a Wistar-Furth (WF) genetic background by denDekker et 
al [137]. The Cop allele at the Mcs1b locus confers resistance to DMBA induced 
mammary carcinogenesis. The Mcs1b locus acts in a mammary gland independent 
manner [137]. Mammary glands from susceptible or Mcs1b resistant donor genotypes 
were transplanted into the interscapular fat pads of susceptible or Mcs1b resistant 
recipient rats. The recipient rats were then given a single dose of DMBA at fifty to fifty 
five days of age. Tumor outcome was checked at fifteen week post DMBA administration 
on the transplanted mammary gland. The donor genotype, but not the recipient genotype 
had a significant effect on tumor outcome, suggesting a mammary gland independent 
mechanism for the Mcs1b locus. The authors also proceeded to look for sequence 
variation in open reading frames of Mcs1b encoded genes between susceptible and Mcs1b 
resistant rats in an attempt to identify causative genes. No variation was identified in the 
coding regions of genes in the Mcs1b locus. With this observation, it was hypothesized 
that the Mcs1b variant is present in a non-coding region and is responsible for differential 
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expression of Mcs1b encoded genes. Since the Mcs1b locus acts in a mammary gland 
independent manner, the expression assays were performed on mammary tissue extracts. 
Mitogen-Activated Protein Kinase Kinase Kinase 1 (Map3k1), GC-Rich Promoter 
Binding Protein 1 (Gpbp1) and Mesoderm Induction Early Response 1, Family Member 3 
(Mier3) were differentially expressed between the susceptible and Mcs1b resistant 
mammary glands that were not exposed to DMBA. However, only Mier3 was 
differentially expressed between susceptible and Mcs1b resistant mammary glands with 
DMBA exposure. Mammary transcript levels were lower in the Mcs1b resistant 
mammary glands compared to the susceptible mammary glands for all three genes. Mier3 
had a higher expression in tumors as compared to adjacent disease free tissue [137]. A 
Mier3 variant (Mier3-alt5’P) which uses an alternative 5’start site was also identified. 
This variant had a higher expression in susceptible mammary glands as compared to 
Mcs1b resistant mammary gland. Since there are two variants of Mier3 being quantified 
in the rat mammary gland the variant previously referred to as Mier3 will be referred to 
as the full-length variant of Mier3 and the variant with the alternate 5’ start site will be 
referred to as Mier3-alt5P. 
The next step of the above investigation was directed toward localizing Mier3 
expression in the mammary gland. The rat mammary gland is a complex tissue. It 
undergoes most of its development after birth in phases which run parallel to sexual 
development and reproduction. The rudimentary mammary gland present at birth 
undergoes development once puberty begins as a result of changes in sex hormone levels. 
Structurally, the rat mammary gland is a tree like structure, consisting of a network of 
ducts and lobules. The mammary gland develops ductal structures which consist of 
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terminal end buds (TEB). These structures grow and branch throughout the mammary 
gland. The TEBs consist of a hollow central lumen which is lined by layers of cells. The 
lumen is surrounded by a layer of luminal epithelial cells which are surrounded by a layer 
of basal epithelial or myoepithelial cells which are further lined by a basement 
membrane. The tip of the growing end of TEBs consist of cap cells, which are loosely 
adhering epithelial cells that lack cytoplasmic polarity, steroid receptors, and an 
organized cytoskeleton [208]. Apart from the ductal structures, the mammary gland 
comprises the mammary fat pad which contains fibroblasts, endothelial cells, leukocytes 
and adipocytes [209]. MIER3 is an uncharacterized gene with a protein product localized 
to the nucleus [137]. To visualize Mier3, Dr. Xu performed immunohistochemistry 
staining for Mier3 in Mcs1b rat mammary gland tissue. He identified that Mier3 is not 
uniformly expressed throughout mammary gland tissue, but is specific to a sub-
population of epithelial cells lining the duct (figure 9). Also, as mentioned above, the 
Mier3 variant (Mier3-alt5’P) with an alternative 5’ transcriptional start site is 
differentially expressed between Mcs1b resistant and susceptible mammary glands. 
Differentially expressed 5’ start variants are typically indicative of cell or tissue type 
specific expression. It is hypothesized that differential expression of Mier3 in rat 
mammary epithelial cells (MECs) explains the reduced susceptibility to DMBA induced 
mammary carcinogenesis in resistant Mcs1b rats compared to susceptible WF rats. To 
test this hypothesis, Map3k1, Gpbp1, full-length Mier3 and Mier3-alt5’P transcript levels 
were compared between mammary epithelial cell enriched extracts (MEC extracts) 
obtained from Mcs1b resistant and susceptible mammary glands with and without DMBA 
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exposure. In addition, the MEC extracts were also characterized by quantifying the 
number of luminal and basal epithelial cells present. 
Results 
Immunofluorescence of Rat Mammary Gland Was Not Specific 
The rat cervical mammary gland sections were stained for Mier3 (stained red in 




Figure 9. Rat Mammary Gland Stained by Immunohistochemistry for Mier3. The 
above tissues were stained by Dr. Xu. Cervical mammary glands were sectioned and 
stained for Mier3 by immunohistochemistry. The first panel shows an H&E stained 
section of the Mcs1b rat mammary gland under 10x and 20x magnification. The second 
panel shows a control section stained for IgG antibody under 10x and 20x magnification. 
The third panel shows a mammary tissue section stained for Mier3 antibody under 10x 
and 20x magnification. Mier3 appears to be expressed in cells surrounding the duct 
compared to the rest of the tissue section. 
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peanut lectin (PNL) antibody (stained green in images). The microscope settings used to 
visualize the tissue did not capture any tissue auto fluoresce as shown in figure 10A. The 
Mier3 antibody used binds to Mier3 successfully as shown in figure 10B. However, the 
Mier3 secondary antibody by itself appeared to bind tissue nonspecifically when used 
without the Mier3 primary-antibody, as seen in figure 10C. The FITC conjugated PNL 
antibody by itself also appeared to bind the tissue nonspecifically as well, as seen in 
figure 10D. This non specificity although minimal in both cases (Figure 10C and figure 
10D) was amplified to a much greater extent when the Mier3 secondary antibody was 
used in conjunction with FITC conjugated PNL antibody, as represented in figure 10E. 
Thus, although the Mier3 antibody appears to stain MECs in figure 10E, we cannot be 
certain that the Mier3 secondary antibody and FITC conjugated PNL antibody staining 
was specific. 
Quantification of Luminal Epithelial and Basal Epithelial Populations within MEC 
Extracts 
The isolation of single cell suspensions enriched for MECs was optimized from 
the protocol found in [210]. Aliquots of MEC extracts were analyzed by flow cytometry 
with the aim of quantifying luminal and basal cell populations in Mcs1b and susceptible 
WF rats with DMBA exposure and without. Single cells were identified from the 
population based on forward and side scatter widths. Dead cells were gated out of the 
single cell populations by using a viability stain. Cells that were CD45+ and CD31+ were 
gated out, as these were hematopoietic and endothelial cells, respectively. Next, the 
selected cell population was separated into basal and luminal cell populations, based on 






























Figure 10. Rat Mammary Gland Immunofluorescence Images. Rat cervical mammary 
gland sections were stained for Mier3 (stained red in images) and epithelial cells were 
visualized by staining with FITC conjugated peanut lectin (PNL) antibody (stained green 
in images). B to E show mammary gland tissues stained by different combinations of 
antibodies. A is a picture of the negative control where the mammary gland is not stained 
with any antibody and it shows no fluorescence. B is a picture of mammary gland tissue 
stained by Mier3 primary and secondary antibody. C is a picture of mammary gland 
stained only by Mier3 secondary antibody. There appears to be some non-specific 
binding which is picked up by the red filter. D is a picture of mammary gland stained 
only by FITC conjugated PNL antibody. There appears to be some non-specific binding 
which is picked up by the green filter. E represents the rat mammary gland stained for 
mammary epithelial cells by FITC conjugated PNL and Mier3 secondary antibody. The 
non-specificity of the Mier3 secondary antibody seems to be amplified by the FITC 
conjugated PNL. F shows mammary gland stained by FITC conjugated PNL and Mier3 
primary and secondary antibodies.
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CD24 expression levels. CD24+CD29hi are the basal cell population while 
CD24+CD29med are the luminal cell population. 
The effects of genotype and DMBA exposure on the differences in expression 
levels were analyzed by performing a two-way ANOVA. This was followed by post hoc 
t-tests. The results are summarized in table 8. Basal cell numbers were not different 
between Mcs1b resistant and susceptible MEC extracts with DMBA exposure (p=0.7996) 
or without DMBA exposure (p=0.7866). The effect of Mcs1b genotype was statistically 
significant (p=0.0002) for the luminal cell population. There was also a significant effect 
(p=0.0441) of DMBA exposure on the luminal cell population. When Mcs1b genotypes 
were compared by exposure, luminal cell population levels were significantly different 
with DMBA exposure (p=0.0193) or without DMBA exposure (0.0009). To summarize, 
luminal cell numbers were higher in MEC extracts of Mcs1b resistant females as 
compared to susceptible WF females. 
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Table 8. Analysis of Luminal and Basal Cells from MEC Extracts Obtained at 12 
Weeks of Age from Mcs1b Congenic and WF Rat Mammary Glands
 
 
MEC extracts were analyzed by flow cytometry.  Endothelial and hematopoietic cells and 
dead cells were excluded from the MEC extract to generate the parent extract.  The 
number of luminal MECs and basal MECs were calculated as a percent of the parent 
extract.  Luminal and basal MECs were analyzed by performing a two way ANOVA 
using Mcs1b genotype (G) and DMBA exposure (E) as independent variables.  MEC cell 
numbers were then compared between the genotypes under different conditions of 
DMBA exposure by performing a t-Test. 
  
Target Mcs1b Genotype Exposure G x E Exposure Susceptible Mcs1b resistant t-Test p-value
Luminal MEC 0.0002 0.0441 0.4559 Control 8.68 ± 0.78 (8) 15.94 ± 1.68 (8) 0.0009
DMBA 11.11 ± 1.46 (7) 23.48 ± 4.62 (8) 0.0193
Basal MEC 0.9514 0.3202 0.7142 Control 22.95 ± 2.25 (8) 24.35 ± 3.25 (8) 0.7996
DMBA 26.47 ± 1.84 (7) 25.89 ± 2.80 (8) 0.7866
Two way ANOVA p-value percent of parent population average ± SE (n)
ratio of number of cells to the parent population were square root transformed for analysis purposes
 81 
Gene Expression Analysis in MEC Populations Supports Map3k1, Gpbp1 and Mier3-
Alt5P as Mcs1b Candidate Genes 
Previous studies from our lab discovered that full-length Mier3, Gpbp1, Map3k1 
and Mier3-Alt5P were differentially expressed between susceptible WF and resistant 
Mcs1b congenic mammary glands without DMBA exposure. However, only full-length 
Mier3 was differentially expressed between WF and Mcs1b congenic mammary glands 
with DMBA exposure. Studies from our lab also identified that Mier3-Alt5P transcript 
was differentially expressed between WF and Mcs1b mammary tissue, and this difference 
was not observed between spleen, ovarian or thymus tissues. Also, 
immunohistochemically stained mammary glands showed that full-length Mier3 was 
more highly expressed in cells surrounding the mammary duct compared to surrounding 
mammary tissue. This led to the hypothesis that Mcs1b MECs differentially expressed 
full-length Mier3, Map3k1, Gpbp1 and Mier3-Alt5P compared to WF MECs. To test this 
hypothesis, I performed qPCR for these genes in MEC extracts obtained from 12 week 
old rats that were administered DMBA at 50-55 days of age. Mcs1b rats were compared 
to susceptible WF rats. These rats were also grouped based on DMBA exposure. 
The effects of genotype and DMBA exposure on the differences in expression 
levels were analyzed by performing a two-way ANOVA and this was followed by post 
hoc t-tests. The results are displayed in table 9. Two Mier3 probes were used to test for 
two of the isoforms of Mier3 expressed in the mammary gland. The probe referred to as 
Mier3 amplified the full-length variant quantified by denDekker et al whereas, Mier3-
alt5P referred to the variant with an alternative 5’ start site [137]. The effect of Mcs1b 
genotype was statistically significant (P < 0.05) for 
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Table 9. Analysis of Mcs1b Candidate Genes from MEC Extract Obtained at 12 
Weeks of Age from Mcs1b Congenic and WF Rat Mammary Glands 
 
Mier3 refers to the full length variant of Mier3 
MEC extracts were aliquoted for gene expression analysis. Expression was calculated by 
performing QPCR.  Differences in expression levels were analyzed by performing a two 
way ANOVA using Mcs1b genotype (G) and DMBA exposure (E) as independent 
variables.  Expression for every gene was then compared between the genotypes under 
different conditions of DMBA exposure by performing a t-Test. 
  
Target Mcs1b Genotype Exposure G x E Exposure Susceptible Mcs1b resistant t-Test p-value
Map3k1 0.0001 0.0452 0.7883 Control 1.353 ± 0.138 (12) 0.871 ± 0.123 (19) 0.0170
DMBA 1.848 ± 0.274 (12) 1.000 ± 0.111 (14) 0.0058
GpBp1 0.0477 0.1199 0.0041 Control 1.257 ± 0.111 (12) 0.842 ± 0.052 (19) 0.0007
DMBA 1.074 ± 0.108 (12) 1.192 ± 0.088 (14) 0.4003
Mier3 0.7230 0.6785 0.1500 Control 0.932 ± 0.124 (12) 1.216 ± 0.164 (19) 0.2250
DMBA 1.274 ± 0.195 (12) 1.086 ± 0.130 (14) 0.4177
Mier3-Alt5P 0.0004 0.3538 0.2987 Control 1.481 ± 0.151 (12) 0.994 ± 0.150 (19) 0.0381
DMBA 1.875 ± 0.311 (12) 0.914 ± 0.126 (14) 0.0059
Two way ANOVA p-value Fold change, target vs Rplp2 ± SE (n)
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Map3k1 (p=0.0001), Gpbp1 (p=0.0477) and Mier3-Alt5P (p=0.0004). Full-length Mier3 
transcript levels were not different between Mcs1b resistant and susceptible MEC 
extracts with DMBA exposure (p=0.2250) or without DMBA exposure (p=0.4177). 
There was a significant effect of DMBA exposure in Map3k1 levels (p=0.0452). There 
was a significant interaction effect between Mcs1b genotype and DMBA exposure for 
Gpbp1 (p=0.0041). When Mcs1b genotypes were compared by exposure, Map3k1 
(p=0.0170), Gpbp1 (p=0.0007) and Mier3-Alt5P (p=0.0381) transcript levels were 
different between genotypes in groups that were not exposed to DMBA, and only 
Map3k1 (p=0.0058) and Mier3-Alt5P (p=0.0059) were different between genotypes in 
groups that were exposed to DMBA. Map3k1 and Mier3-Alt5P transcript levels were 
lower in resistant Mcs1b MEC extracts compared to susceptible WF MEC extracts. 
Discussion 
Immunofluorescent Staining of Mier3 and MECs in Rat Mammary Gland Tissue 
Sections 
Mammary gland tissues sections were stained with Mier3 antibody and FITC 
conjugated PNL antibody to visualize Mier3 protein and MECs, respectively. Selected 
filters did not reveal that any of the tissues auto-fluoresced. Further, the Mier3 antibody 
used indicated successful display of sites of Mier3 expression; it seemed the Mier3 
secondary and FITC conjugated PNL antibodies used were not specific. The Mier3 
secondary antibody stained cells even when the primary antibody was not present. The 
Mier3 secondary antibody staining was not as strong without the use of the primary 
antibody. However, once FITC conjugated PNL was used in combination with the Mier3 
secondary antibody, the non-specificity associated with the Mier3 secondary antibody 
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and FITC conjugated PNL antibody was amplified. It appears like the secondary Mier3 
antibody interacted with FITC conjugated PNL. Thus, there is non-specificity associated 
with the Mier3 secondary antibody and FITC conjugated PNL. The experiment was not 
continued due to the lack of time needed to troubleshoot this experiment. Future 
experiments designed to identify cellular localization of Mier3 gene products would need 
to address this issue and identify antibodies that are specific to Mier3 and MECs 
individually and do not cross-react.  
Characterization of MEC Extract 
The goal of this aim was to characterize the MEC extract to support work toward 
identifying the mechanism of reduced mammary cancer susceptibility associated with 
Mcs1b. Two aspects of MEC extract were quantified. The number of luminal and basal 
mammary epithelial cells, and transcript levels of full-length Mier3, Gpbp1, Map3k1 and 
Mier3-Alt5P present in the MEC extract. The number of luminal and basal cells and full-
length Mier3, Gpbp1, Map3k1 and Mier3-Alt5P expression levels were quantified in 
MEC extracts obtained from Mcs1b resistant and susceptible mammary glands with or 
without DMBA exposure.  
Since the year 2000, breast cancer has also been classified into molecular 
subtypes based on global gene expression profiles. These five categories, namely luminal 
A, luminal B, Her2-enriched, basal like and normal breast like group [211]are found 
across all breast cancer stages from in situ carcinomas, inflammatory tumors, and 
metastatic tumors [212]. Luminal A tumors account for about 50% of invasive breast 
cancer. Luminal A tumors are estrogen receptor (ER)+, progesterone receptor (PR)+ and 
Her2-. They are less proliferative, poorly sensitive to chemotherapy, but are responsive to 
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hormone therapy. Luminal B tumors are ER+, PR+ and may be Her2+ or Her2-. Luminal 
B tumors have low expression of hormone receptors and they account for 20% of 
invasive breast cancers. Tumors that overexpress Her2/neu are usually ER-, PR- and have 
high expression of Her2/neu receptors. These tumors mostly have lymph node metastasis, 
are of a high grade, and account for 15% of invasive breast cancers. Basal like mammary 
tumors are similar to basal epithelial and normal myoepithelial cells. It is usually ER-, 
PR-, Her2/neu- and are CK5/6+ or EGFR+. They account for 15% of aggressive breast 
cancers. Basal like tumors are mostly high grade invasive cancers and special subtypes of 
intraductal carcinomas with good prognosis. Luminal B, Her2-enriched and basal like are 
generally resistant to hormone therapy but sensitive to chemotherapy [213]. In summary, 
mammary tumor subtypes are associated with tumor prognosis and therapeutic responses. 
My studies indicate that Mcs1b resistant mammary glands contain a larger 
population of luminal cells with or without DMBA exposure as compared to Mcs1b 
susceptible mammary glands. Also, exposure to DMBA results in an increased number of 
luminal epithelial cells in both Mcs1b resistant and susceptible WF mammary glands. 
This indicates that because resistant rats have a larger proportion of luminal epithelial 
cells with DMBA and without that more MECs might survive the DNA-damaging effects 
of DMBA or the resistant genotype might be better at replacing MECs. Never the less, 
results from my experiments suggest that luminal epithelial cell populations are a 
potential target of DMBA carcinogenesis and functional differences in this population 
may confer genetically determined differences in susceptibility. Future experiments 
should be directed towards closely looking at this population for potential expression 
level differences and effects on carcinogenesis. 
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I also found that Map3k1, Gpbp1 and Mier3-Alt5P were differentially expressed 
between Mcs1b resistant and susceptible mammary glands that had not been exposed to 
DMBA. However, only Map3k1 and Mier3-Alt5P were differentially expressed between 
susceptible and resistant MEC extracts after DMBA exposure. The interaction between 
genotype and DMBA exposure was significant for Gpbp1 expression, but Gpbp1 was not 
differentially expressed between Mcs1b resistant and susceptible mammary glands that 
were exposed to DMBA. Thus, Map3k1, Gpbp1 and Mier3 are likely candidate 
susceptibility genes. 
MAP3K1 is a serine/threonine kinase which was identified in 1994 [214]. It is 
known to be a part of ERK and JNK kinase pathways and the NF-kappa-B pathways. 
Breast cancer susceptibility SNP rs889312 marks a breast cancer risk associated locus 
identified by Easton et al.[131] This locus is orthologous to the rat Mcs1b locus. The 
human haplotype block associated with risk contains annotated genes, MAP3K1, 
C5ORF35 and MIER3. A recent study found that miRNA targeting of MAP3K1 
significantly suppressed proliferation and invasion of breast cancer cells [215]. Somatic 
mutations in the cancer genome atlas study found Map3k1 alterations were enriched in 
the luminal A subtype of breast cancer. Map3k1 variations were mainly inactivating 
frameshift deletions or insertions [216]. However, the exact role MAP3K1 plays in breast 
cancer remains to be elucidated. My studies show that Map3k1 expression increases on 
DMBA exposure and that Map3k1 levels are significantly lower in Mcs1b resistant MEC 
extract as compared to susceptible extracts. This makes Map3k1 a strong candidate for 
the Mcs1b locus. 
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GPBP1 is an uncharacterized gene. It was first identified in atherosclerotic 
plaques but later a more ubiquitously expressed variant was identified. It functions as a 
GC-rich promoter-specific transcription factor. Thus this protein may bind DNA and 
perform transcription factor activities. My experiments show that there is a significant 
effect of genotype on Gpbp1 expression. DMBA exposure has the opposite effect on 
Gpbp1 expression in Mcs1b resistant and WF susceptible rat MEC extracts. DMBA 
causes an increase in Gpbp1 expression in Mcs1b resistant rat MEC extracts and a 
decrease in expression in susceptible rat MEC extracts. The significance of this 
observation is yet unknown and warrants further investigation. 
Previous investigations by denDekker et al. identified Mier3 as a candidate gene, 
but results from my experiments showed no variation in the full-length variant of Mier3 
expression levels between genotypes, with or without DMBA exposure. However, the 
alternative splice variant identified by denDekker et al. was found to follow the same 
trend that was previously observed for the full-length variant of Mier3. I found that the 
Mier3-alt5P was differentially expressed between Mcs1b resistant and susceptible MEC 
extracts both with and without DMBA exposure. Thus, Mier3 continues to be a candidate 
gene that is potentially responsible for Mcs1b associated mammary carcinoma resistance. 
It is possible that Mier3-alt5P is the main Mier3 variant present in MECs such that the 
difference observed by denDekker et al. in whole mammary gland tissue is now observed 
in Mier3-alt3P transcripts in MECs. Alternative splicing is one of the most important 
ways mammals maintain protein diversity. Alternative splicing is used to generate 
multiple proteins from the same locus. There are two major advantages to alternative 
splicing, it creates more functional proteins from the same mRNA and it selects the 
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isoform used in the cell. Including or skipping exons usually alters protein structure and 
thereby protein functions. Alternative non-coding or partially coding exons usually 
harbor cis regulatory elements that control subcellular localization, stability and 
translational efficiency of the encoded protein; thereby, controlling protein localization 
and density. Alternate splicing is usually common during development and in cell lineage 
differentiation [217, 218]. Although we are aware of the sequence variation of the Mier3 
mRNA isoform, we do not have much information regarding its function.  
The congenic animals used differ genetically, only at the Mcs1b locus. Resistant 
female rats differentially express Mier3-alt5p, Map3k1, Gpbp1 compared to female rats 
harboring a susceptible WF allele at Mcs1b. There seems to be a larger reserve of luminal 
mammary epithelial cells in Mcs1b resistant mammary glands compared to susceptible 
WF rats. Therefore, any one or a combination of these observed differences could be 
responsible for Mcs1b associated resistance to mammary cancer. More empirical work is 
necessary to determine the mechanisms by which Mier3-alt5p, Map3k1 and Gpbp1 are 
working to alter mammary carcinoma susceptibility. 
Materials and Methods 
Generating WF.Cop Congenic Line N3 
All animals used for this study were housed by the University of Louisville 
Research Resources Center Animal Facility. All protocols followed were approved by the 
University of Louisville IACUC. 
WF.Cop line N3 was developed through a backcross of Mcs1b resistant line T to 
WF rats strain. The resultant pups were genotyped using informative markers as decribed 
in chapter 2 and chapter 3. The list of markers used is provided in table 10. A   
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Table 10. Informative Makers Used to Genotype Congenic Line N3  

























































































recombinant rat with the Cop allele represented in the congenic line N3 was selected and 
further backcrossed to WF females to expand the line. Rats that are heterozygous Cop at 
the N3 locus were inbred to generate rats that were homozygous Cop at the N3 locus. 
Congenic line N3 was then fixed and rats were used for experiments. Females were 
administered DMBA at fifty to fifty five days of age and were euthanized at twelve 
weeks of age. Cervical, abdominal and inguinal mammary glands and spleens were 
collected postmortem. 
Isolation of Mammary Epithelial Cell Enriched Extract 
MEC extract was prepared as previously described [210]. For each rat, both 
abdominal and inguinal mammary glands without lymph nodes were excised and kept 
separately in GIBCO DMEM/F12 media (Invitrogen). These mammary glands were 
scissor minced and digested in 10 ml of DMEM/F12 containing 0.01 g/ml of type III 
Collagenase (Worthington) for 2 hours at 37˚C with gentle horizontal shaking. 0.2 mg/ml 
of DNase I (Worthington) was then added to this digest for ten minutes under vigorous 
shaking. This extract was then centrifuged and the supernatant fat was discarded. The 
pellet was then washed with DMEM/F12. The cells were monodispersed by dissolving 
the pellet in 2 ml of Hank’s balanced salt solution containing 0.025% trypsin and 6.8 mM 
EDTA. This reaction was stopped after 5 minutes by adding 4 ml of DMEM/F12 
containing 10% fetal bovine serum (FBS). The cells were centrifuged and resuspended in 
2 ml of DMEM/F12 containing 10% FBS and passed through a 40 μm cell strainer. The 
centrifuge tube was rinsed with another 2 ml of DMEM/F12 containing 10% FBS and 
passed through the same 40 μm cell strainer to collect a single cell suspension of MEC 
extract. 
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Antibody Staining and Flow Cytometric Analysis of MEC Extract 
MEC extract was stained as previously described [210]. Single cell suspensions 
were stained using antirat CD24, CD29, CD31 CD45 and live/dead stain (BD 
Pharmingen) antibodies. The MEC extract was centrifuged and suspended in phosphate 
buffer saline (PBS). Cells were stained with 0.5 μg of each antibody per 106 cells in 200 
μl PBS for 30 minutes at 4˚C in the dark. The volume was brought up to 1 ml and 
centrifuged. The cells were washed and later fixed using fixation buffer (1 part 4% 
formaldehyde to 3 parts PBS) for 10 minutes at room temperature. Samples were washed 
and resuspended in 600 μl PBS. Cells were counted using a flow cytometer and analyzed 
using FACS Diva. 
Gene Expression Assays 
RNA was isolated from the MEC extract using the MagMAX
TM
 -96 Total RNA 
isolation kit (Ambion). Total RNA was quantified using Nanodrop 1000 (Fisher 
Scientific). cDNA was synthesized using 1μg total RNA, 0.5x RNAsecure, 5μM random 
hexamers, 25ng/μL oligo(dT18), and 0.5 mM dNTPs in a final volume of 20μL. The 
reaction mixtures were incubated for 5 minutes at 65º C. Then 1× first strand buffer, 
100mM DTT, and 1μL Superscript III (Life Technologies) was added to each reaction 
mixture. Reactions were incubated 5 m at 25º C, 1 h at 50º C, and 15 m at 70º C. TaqMan 
QPCR primers and MGB probes (Applied Biosystems) (sequences are in table 11), 
designed by denDekker et al. [137], were used in a 20μl TaqMan QPCR reaction. Each 
reaction comprised of 1× TaqMan Buffer A (Applied Biosystems); 3.5 mM MgCl2; 
dATP, dCTP, dGTP, and dTTP at 200 μM each; experimental primers at 500 nM each; 
200 nM TaqMan experimental probe (Applied Biosystems) and 0.4 units of Taq Gold  
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This table displays the primer and probe sequences used for gene expression analysis on 
Mcs1b MEC extracts.  The genes analyzed are Rplp2, Map3k1, Mier3, Gpbp1 and Mier3-
Alt5P.
Assay Name Forw ard Primer Sequence (5' to 3') Reverse Primer Sequence (5' to 3') Probe Sequence (5' to 3')
Rplp2 TGAACGACTCAACAAGGTCATCA CAACACCCTGAGCGATGACA VIC-CTGAATGGAAAGAATATTGAG
Map3k1 TCCTCATATTGTCAGTACCGATGTC TTGCAAGGCAAAGGCTAAGAG 6FAM-CCTGTTGAAATCAGGTATAA
Mier3 CGAAAGGTACTGCTGTAATGGAAA GCACTCCTCTTCAGTCCAAGCT 6FAM-CGTCTCAAGAAGGAATG
Gpbp1 GAGTAGAAGAGGAGCATGAAGATGAA TGGTGAGTACTATTGCTGTTATGCAA 6FAM-CTCAGAGAAGGATGACGAC
Mier3-Alt5P ATGGCGGAGGCTTCCTTT TCAAAATCATGATCCTCAGAAGACA 6FAM-AGCCCAGTTGGGTCT
Rat Mcs1b  Target and Rplp2 Primers and Probe Sequences Used for QPCR
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DNA Pol (Applied Biosystems). In case of Rplp2, primers were at the concentration of 
125 nM each and 200 nM rodent Rplp2 probe was used. Real-time QPCR was run on an 
Applied Biosystems Step One Plus real-time PCR machine. Real-time QPCR was run at 
50°C for 2 min and 95°C for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 1 
min. The fluorochrome FAM was used on target gene probes and VIC was used on the 
rodent Rplp2 probe (Applied Biosystems). Analysis was performed by the delta-delta CT 
method using Rplp2 as the internal control. Each sample measurement is an average of 
three technical replicates. Data were analyzed by performing a two way ANOVA and 
post hoc t-tests. 
Immunofluorescence of Transverse Sections of Rat Mammary Glands 
Rat right cervical mammary glands were isolated and fixed in zinc fixative for 16-
24 hours. The mammary glands were then transferred into 70% ethanol. The glands were 
then submitted to the UofL pathology core for paraffin embedding and tissue sectioning. 
Each tissue section was deparaffinized and rehydrated by transferring it successively into 
decreasing concentrations of alcohol. The tissue was rinsed in water and immersed in 
10mM tris EDTA and microwaved on high for 20 minutes. The tissue was allowed to 
cool at room temperature and rinsed in PBS. The tissue section was blocked with PBS 
containing 0.5% triton, 5% normal donkey serum. The blocking reagent was tapped out 
of the slide which was then incubated with primary antibody (rabbit polyclonal Mier3- 
ab69877- abcam, negative control for rabbit IgG Ab-1- thermoscientific, FITC 
conjugated Peanut lectin (PNL)-sigma L7381, Anti-Rat CD90 BD Pharmigen) in PBS 
overnight at 4˚C. The tissue was washed with PBS. The tissue was then incubated with 
secondary antibody (donkey anti-rabbit Alexa Fluor 546 conjugate, ThermoFisher 
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Scientific) in PBS at room temperature for 1-1.5 hours. The tissue was washed with PBS 
and was permanently mounted. The tissue was visualized using a confocal microscope 
and representative images were taken. 
Genomics and Statistical Analysis  
Quantitative PCR (QPCR) data were analyzed using the delta-delta CT method 
using Rplp2 as the internal control. qPCR data were analyzed by performing a two way 
ANOVA and post hoc t-tests. Independent variables for comparing mammary gland 
transcript levels were genotype and DMBA exposure. The flow cytometry data were 
analyzed using a two way ANOVA. Data were transformed prior to analysis by taking 
the square root of the ratio of the cell count to the gated parent population. Genotype and 





Breast cancer is a complex disease characterized by its environment, genetic and 
epigenetic components. Many approaches have been used to study the mechanisms 
associated with breast cancer, each with their own advantages and disadvantages. With 
every study we gain new insight into this multifaceted collection of diseases known as 
breast cancer. The laboratory rat has been used extensively to study breast cancer. There 
are several rat genomic loci that associate with breast cancer susceptibility. This study 
focused on two such loci, namely Mcs3 and Mcs1b, using congenic rats as a model of 
breast cancer susceptibility.  
The Mcs3 locus was initially predicted across two peak markers D1Mit11 and 
D1Wox6 on rat chromosome 1 [173]. Rat Mcs3 had not been physically confirmed; and 
thus, its location on chromosome 1 hadn’t been fine-mapped. In this study, the Mcs3 
locus was physically confirmed and mapped to 25.8 MB region on rat chromosome 1 
using multiple congenic lines. Mcs3 is highly relevant as it contains five genes and 1 SNP 
that have been associated with breast cancer susceptibility. Bioinformatic analysis of the 
locus and it orthologous region in humans led to the identification of 3 candidate genes 
PAK1, ILK and, IL18BP. Among these five genes PRC1, PAK1, ILK and IL18BP are 
expressed both in rats and humans. PAK1 downstream pathways play an important role in 
development and maintenance of metastatic phenotype in breast cancer cells. PAK1 was 
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also shown to be a predictor of recurrence and tamoxifen resistance in post-menopausal 
breast cancer [198]. ILK may be an important marker since increased expression of ILK is 
associated with aggressive progression and poor prognosis of breast cancer [200]. 
IL18BP regulates the activity of interleukin 18. IL-18 expression is significantly higher in 
malignant breast tumor tissue as compared to breast tissue of patients with benign breast 
disease [202]. 
Overall, the Mcs3 congenic rats provide an experimental organism which could be 
used in the future to perform functional genetic studies which can be translated to human 
breast cancer. Studying the Mcs3 locus is highly relevant because the exact mechanism 
by which Mcs3 contributes to mammary carcinoma susceptibility is not known. Any of 
the three candidate genes mentioned above could be responsible for the reduced 
mammary carcinoma susceptibility associated with Mcs3 or the Mcs3 locus could contain 
a novel breast cancer susceptibility gene. 
In comparison to Mcs3, considerable research had been done on the Mcs1b locus 
prior to my studies involving this QTL. The Mcs1b locus had been physically confirmed 
and fine mapped [181]. It was known that the Mcs1b locus acted in a mammary gland 
independent manner and full-length Mier3 variant was predicted as the Mcs1b candidate 
gene [137]. It was also known that Mier3 was expressed in mammary epithelial cells 
surrounding mammary ducts. There was a Mier3 splice variant with an alternate 5’ start 
site (Mier3-alt5P) that was more highly expressed in Mcs1b mammary glands compared 
to susceptible mammary glands [137]. One of the goals of this study was to characterize 
Mcs1b mammary epithelial cells with respect to proportion of luminal and basal epithelial 
cells and expression of full-length Mier3, Map3k1, Gpbp1 and Mier3-alt5P compared to 
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DMBA induced mammary carcinoma susceptible WF rats. This study was performed on 
MEC extracts that were enriched for mammary epithelial. MEC extracts were obtained 
from mammary glands by enzymatic digestion. The MEC extract was then aliquoted for 
antibody staining and cytometric analysis, and qPCR expression analysis assays. In 
cytometric analysis, single cells were identified from the population based on forward 
and side scatter widths. Dead cells were gated out of the single cell populations by using 
a viability stain. Cells that were CD45+ and CD31+ were gated out, as these were 
hematopoietic and endothelial cells, respectively. Next, the selected cell population was 
separated into basal and luminal cell populations, based on CD29 and CD24 expression 
levels. CD24+CD29hi are the basal cell population while CD24+CD29med are the 
luminal cell population 
Findings from this study indicate, the proportion of luminal MECs was higher in 
Mcs1b resistant MEC extracts compared to susceptible MEC extracts. The significance of 
this finding is unknown. However, this observation suggests that luminal MECs are 
potentially the target cells of DMBA induced carcinogenesis and future mechanistic 
studies could be conducted in luminal MECs. Expression assays on MEC extracts suggest 
that Map3k1, Gpbp1 and Mier3-alt5P are potential Mcs1b candidate genes [137]. Rat 
Map3k1, Gpbp1 and Mier3-alt5P transcripts were expressed at a significantly lower level 
in Mcs1b resistant MEC extracts as compared to susceptible MEC extract without DMBA 
exposure. Both Map3k1 and Mier3-alt5P continued to remain expressed at a significantly 
lower level in Mcs1b resistant MEC extracts as compared to susceptible MEC extract 
with DMBA exposure. There was a significant interaction between genotype and DMBA 
exposure for Gpbp1 expression. The susceptible WF and Mcs1b rats only differ in their 
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genome at the Mcs1b locus. The results suggest that Map3k1, Gpbp1 and/or Mier3-alt5P 
are responsible for the Mcs1b associated reduced susceptibility to DMBA induced 
carcinogenesis. 
MAP3K1 is a serine/threonine kinase with a role in ERK and JNK kinase 
pathways, as well as the NF-kappa-B pathway. Breast cancer susceptibility associated 
SNP rs889312 identified by Easton et al. is orthologous to the rat Mcs1b locus and 
nominates MAP3K1, C5ORF35 and MIER3 as breast cancer susceptibility candidate 
genes [131]. A recent study found that miRNA targeting of MAP3K1 significantly 
suppressed proliferation and invasion of breast cancer cells [215]. GPBP1 is an 
uncharacterized gene. It’s predicted function is as a GC-rich promoter-specific 
transcription factor. Thus, Gpbp1 may bind DNA and perform transcription factor 
activities. Previous investigations by denDekker et al. identified Mier3 as a candidate 
gene, but results from my experiments showed no variation in full-length Mier3 
expression levels between genotypes, with or without DMAB exposure. The full-
lengthMier3 was the variant tested by denDekker et. al. However, the alternative splice 
variant Mier3-alt5P was found to follow the same trend that was previously observed for 
Mier3. It is possible that Mier3-alt5P is the main Mier3 variant expressed in MECs. The 
Mier3-alt5P is predicted to include a casein kinase phosphorylation site at the N-terminus 
compared to Mier3 protein. Although we are aware of the sequence variation of the 
Mier3 mRNA isoform, we do not know its function. Therefore, Map3k1, Gpbp1 and/or 
Mier3-alt5P are Mcs1b candidate genes and the luminal mammary epithelial cell 
population is the likely target of DMBA carcinogenesis. 
 99 
Future Directions 
In conclusion, Mcs3 was physically confirmed and mapped to a 25.8 MB region 
on rat chromosome 1 and PAK1, ILK and IL18BP are potential candidate genes. The next 
step for Mcs3 would be to identify if Mcs3 acts in a mammary gland independent manner. 
Once that is completed, expression studies can be performed on the candidate genes 
while continuing congenic studies to further fine map the Mcs3 locus in search of 
potential novel breast cancer susceptibility genes. 
This study suggests the luminal mammary epithelial cell population is a target cell 
population of DMBA carcinogenesis in Mcs1b congenic rats, and that Map3k1, Gpbp1 
and/or Mier3-alt5P are Mcs1b candidate genes. This should be further investigated by 
isolating luminal mammary epithelial cells and performing expression assays to quantify 
Map3k1, Gpbp1 and/or Mier3-alt5P in Mcs1b resistant mammary glands and compare 
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